**Name of journal: World Journal of Biological Chemistry**

**ESPS Manuscript NO: 9688**

**Columns: Review**

**New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases**

Adachi N *et al*. BDNF in brain-related diseases

Naoki Adachi, Tadahiro Numakawa, Misty Richards, Shingo Nakajima, Hiroshi Kunugi

**Naoki Adachi, Tadahiro Numakawa, Shingo Nakajima, Hiroshi Kunugi,** Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan

**Naoki Adachi, Tadahiro Numakawa, Hiroshi Kunugi,** Core Research for Evolutional Science and Technology Program, Japan Science and Technology Agency, Saitama 332-0012, Japan

**Misty Richards,** Albany Medical College, Albany, NY 12208, United States

**Author contributions:** Adachi N wrote and edited the paper; Numakawa T wrote and edited the paper; Richards M wrote and edited the paper; Nakajima S edited the paper; Kunugi H edited the paper.

**Supported by** The Health and Labor Sciences Research Grants (Comprehensive Research on Disability, Health, and Welfare H21-kokoro-002) (H. K.); and the Core Research for Evolutional Science and Technology Program, CREST, Japan Science and Technology Agency (JST) (T.N., N.A. and H.K.); the Naito Foundation (N.A), the Takeda Science Foundation (T. N.); a grant from Grant-in-Aid for Scientific Research (B), (JSPS KAKENHI) (T. N.), No. 24300139; and Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI) (T. N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, No. 25640019

**Correspondence to: Tadahiro Numakawa, PhD,** Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. numakawa@ncnp.go.jp

**Telephone:** +81-42-3412711-5132 **Fax:** +81-42-3461744

**Received:** February 23, 2014 **Revised:** June 30, 2014

**Accepted:** August 27, 2014

**Published online:**

**Abstract**

Brain-derived neurotrophic factor (BDNF) attracts increasing attention from both research and clinical fields because of its important functions in the central nervous system. An adequate amount of BDNF is critical to develop and maintain normal neuronal circuits in the brain. Given that loss of BDNF function has been reported in the brains of patients with neurodegenerative or psychiatric diseases, understanding basic properties of BDNF and associated intracellular processes is imperative. In this review, we revisit the gene structure, transcription, translation, transport and secretion mechanisms of BDNF. We also introduce implications of BDNF in several brain-related diseases including Alzheimer’s disease, Huntington’s disease, depression and schizophrenia.

**Key words:** Brain-derived neurotrophic factor; Transcription; Transport; Secretion; Neurodegenerative disorders; Psychiatric disorders

**Core tip:** Brain-derived neurotrophic factor (BDNF) attracts increasing attention from both research and clinical fields because of its important functions in the central nervous system. An adequate amount of BDNF is critical to develop and maintain normal neuronal circuits in the brain. Given that loss of BDNF function has been reported in the brains of patients with neurodegenerative or psychiatric diseases, understanding basic properties of BDNF and associated intracellular processes is imperative. In this review, we revisit the gene structure, transcription, translation, transport and secretion mechanisms of BDNF. We also introduce implications of BDNF in several brain-related diseases including Alzheimer’s disease, Huntington’s disease, depression and schizophrenia.

Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H. New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases. *World J Biol Chem* 2014; In press

**INTRODUCTION**

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin (NT) family, was purified in 1982 from pig brain as a cell survival-promoting factor for sensory neurons[1] about 30 years after the discovery of nerve-growth factor (NGF)[2]. In the past three decades, two other neurotrophins, neurotrophin 3 (NT3) and neurotrophin 4 (NT4), have been identified in the mammalian brain and their function in neuronal survival, neurite outgrowth, and synaptic plasticity in the nervous system extensively investigated[3]. Each neurotrophin has a common receptor p75NTR and a specific tropomyosin-related kinase receptor (Trk); TrkA for NGF, TrkB for BDNF and NT4, TrkC for NT3. All neurotrophins are synthesized as 32 kD precursor proteins called pro-neurotrophins that are intra- and extracellularly cleaved to produce the mature neurotrophin form[4-6]. Mature neurotrophins bind to Trk receptors with high affinity while pro-neurotrophins preferentially bind to p75NTR[4-6]. Neurotrophins exert their biological function through several signaling pathways activated by Trk receptors or p75NTR after binding of neurotrophins. Binding of the BDNF dimer to TrkB induces dimerization and autophosphorylation of TrkB, resulting in sequential phosphorylation in three intracellular signaling pathways; Mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK), phospholipase Cγ (PLCγ), and phosphatidylinositol 3-kinase (PI3K) pathways[7-10].

BDNF is the most studied and characterized neurotrophin in the central nervous system (CNS) and has received remarkable attention from clinicians because of its importance in the development and maintenance of normal brain functions. This is especially important, as growing evidence suggests a role of BDNF in the pathophysiology of brain-associated illnesses including both neurodegenerative and psychiatric diseases[11,12]. Appropriate intracellular processes including transcription from the BDNF gene, translation to protein, BDNF protein sorting to secretory vesicles, BDNF-containing vesicle transport, and BDNF secretion are essential to achieve normal BDNF functions as well as to activate the signaling pathways after TrkB phosphorylation. As decreased expression levels of BDNF in several brain regions are evident in postmortem studies of patients with the brain-related diseases[11,12], precise knowledge about BDNF gene expression is critical. Specifically, the responsible gene of Huntington’s disease, huntingtin, has been shown to directly regulate intracellular transport of BDNF[13,14]. Furthermore, we recently reported impaired BDNF secretion and TrkB signaling in a cellular model of schizophrenia[15].

In this article, we review both converting (from gene to mature protein) and spatial regulation (transport and secretion) processes of BDNF. We will also highlight recent findings suggesting implications of BDNF in the pathophysiology of the brain-related diseases.

**BDNF GENE STRUCTURE**

BDNF mRNA and protein are abundantly expressed in the hippocampus, cerebral cortex, amygdala, and cerebellum in the mammalian brain[16-19]. Although BDNF is widely expressed in other tissues such as the heart, kidney, lung and testis, BDNF expression is higher in the brain than any other tissue during development[20]. It is also known that BDNF expression is dramatically increased in the rodent visual cortex with a peak at postnatal days 20-40 when visual plasticity is high[21,22].

The BDNF gene consists of at least eight 5’ exons (exon I-VIII) with each respective promoter and one 3’ exon (exon IX) encoding BDNF protein in both human and rodent[23-25] (Figure 1). Pruunsild *et al*[25] recently identified two human-specific exons named exons Vh and VIIIh. Exon Vh has a specific promoter while exon VIIIh is not linked to an independent promoter. Transcription of the BDNF gene is initiated at each of 5’ noncoding exons that are spliced onto the pre-proBDNF protein-coding 3’exon IX[24,25]. Rodent exon I and human exons I, VII and VIII of the BDNF gene contain the ATG sequence from which translation could be started, which could produce the distinct pre-proBDNF proteins with longer amino acid sequences at the N-terminal end of the protein[24,25]. Other exons are untranslated exons, and translation of the transcripts (mRNAs) containing these exons only starts from the ATG sequence located at the exon IX[25]. Moreover, transcription of the BDNF gene terminates at two alternative polyadenylation sites in exon IX, giving rise to two distinct populations of mRNA with either short ([approximately](http://www.iciba.com/approximately) 0.35 kb) or long ([approximately](http://www.iciba.com/approximately) 2.85 kb) 3’ untranslated regions (3’ UTRs)[26,27]. To produce an identical pre-proBDNF protein, the evolutionary change in BDNF gene structure has remained a complex transcription mechanism that results in the expression of multiple BDNF mRNA variants. The diversity of BDNF mRNA leads to different neuronal distribution. The short 3’ UTR BDNF mRNA variant is restricted to the cell body in hippocampal neurons while the long 3’ UTR mRNAs are also observed in dendrites[27], indicating a specific dendritic transport system for the long 3’ UTR BDNF mRNA and local dendritic translation.

**TRANSCRIPTIONAL REGULATION IN BDNF GENE**

Using multiple promoters in BDNF transcription allows for appropriate responses to intracellular processes and varying extracellular environments. Membrane depolarization is a well-known neuronal gene expression regulator, and more than 300 gene transcriptions have been identified as activity-dependent in neurons[28]. The transcription of BDNF in neurons is positively regulated by membrane depolarization induced by seizures[29], sensory stimuli[30-32] and activation of glutamate receptors such as N-methyl-D-aspartate (NMDA) receptors[33-35], suggesting its important function in experience-dependent modifications of neural circuits and brain development. Neuronal activity stimulates transcription initiation of the BDNF gene, which is regulated by elevation of intracellular Ca2+ concentration *via* NMDA receptors (NMDAR) or L-type voltage-gated calcium channels (L-VGCC)[35]. The activity- and Ca2+-dependent transcription of the BDNF gene occurs predominantly through exons I and IV. The promoter region of BDNF exon IV contains three Ca2+-response elements CaRE1, CaRE2 (also known as USF-binding element, UBE) and CaRE3 (also known as calcium response element, CRE)[36-38] (Figure 1). CaRE1 is located at 64-73 bp upstream of the transcription initiation site in exon IV. CaRE2 and CaRE3 are 43-52 bp and 29-36 bp upstream, respectively[38]. Regulation of exon IV transcription via CaRE3 has been extensively investigated. Cyclic AMP-responsive element binding protein (CREB), which is phosphorylated at multiple sites by calcium/calmodulin (CaM)-dependent protein kinases, cAMP-dependent protein kinase (PKA) and MAPK cascades binds to CaRE3/CRE to activate the promoter[37-39]. Knock-in mice with a subtle mutation at the CREB binding site in endogenous CaRE3/CRE showed a disrupted sensory experience-dependent increase of the BDNF exon IV transcript in the cortex[40]. Greenberg and colleagues identified novel transcription regulators for BDNF exon IV such as CaRF (calcium responsive factor) and USFs (upstream stimulatory factors) for CaRE1 and CaRE2, respectively[36,41] (Figure 1). CaRF knockout mice showed reduced exon IV mRNA levels in the cerebral cortex with normal levels in the hippocampus and striatum, suggesting brain region-specific regulation of CaRF-CaRE1 at the BDNF promoter IV[42]. Recently, Zheng *et al*[37] revealed intriguing Ca2+-dependent activation mechanisms of each CaRE, using cultured cortical neurons at DIV 11. Ca2+ entry through NMDAR or L-VGCC stimulated only CaRE1 and CaRE3 but not CaRE2, and CaRE1 and CaRE3 were activated *via* different sets of protein kinases depending on the route of calcium entry[37]. For example, CaRF is essential only for the L-VGCC-induced, not the NMDAR-induced, transcription of BDNF exon IV[37,38], indicating that other transcriptional regulators stimulate the NMDAR-dependent activation of CaRE1. Furthermore, the L-VGCC-dependent CaRE1 activation depends on protein kinase A (PKA), calcium/calmodulin-dependent protein kinase I (CaMKI), and CaMKIV, while CaRF activation requires MEK, PI3K and CaMKII[37,38]. On the other hand, CaRE3 activity is regulated by Ca2+ influx through both L-VGCC and NMDAR. MEK, PI3K, and PKA activity are required in both the L-VGCC - and NMDA-induced CaRE3 activation[37,38]. CaM and CaMKIV are needed in the L-VGCC-induced CaRE3 activation while CaMKI and CaMKIV are required in the NMDAR-mediated CaRE3 activation[37,38]. Although CaREs play a central role in the regulation of BDNF promoter IV, there are also other possible regulators for the promoter including basic helix-loop-helix B2 (BHLHB2) and nuclear factor-κB (NF-κB)[43,44] (Figure 1). Furthermore, neuronal activity stimulates BDNF promoter I as well as promoter IV. Several transcription factor binding sites such as CREB, USFs, myocyte enhancer factor 2D, and NF-κB have been suggested to stimulate BDNF promoter I[45-47], though the regulatory mechanisms have not been elucidated. Futhermore, Timmusk and colleagues have identified a cis-element PasRE (bHLH-PAS transcription factor response element) in both promoter I and IV. They also demonstrated that transcription factors ARNT2 (aryl hydrocarbon receptor nuclear translocator 2, a basic helix-loop-helix (bHLH)-PAS transcription factor) and NPAS4 (neuronal PAS domain protein 4) bind to PasRE (bHLH-PAS transcription factor response element) in both promoters, which is required for full induction of neuronal activity-dependent transcription from each exon[48,49].

Epigenetic regulations in transcription of the BDNF gene have also been reported. Decreased methylation of cytosine residues in CpG dinucleotides (CpG) of BDNF promoter IV, at least in part, mediates neuronal activity-dependent induction of BDNF transcription. Methyl-CpG–binding protein 2 (MeCP2), a member of the methyl-CpG–binding protein family, binds to methylated DNA in the BDNF promoter IV region and functions as a transcriptional regulator[50]. It is still controversial whether MeCP2 functions as an activator or a repressor for BDNF transcription. Because MeCP2 protein is released from the BDNF promoter IV region in response to neuronal activity-induced reduction of CpG methylation, it had been recognized as a transcriptional repressor for the *BDNF* gene[50]. However, both BDNF mRNA and protein levels were decreased in MeCP2-null mice[51], suggesting a possible repressive function of MeCP2 on BDNF expression. Furthermore, a combination mechanism of MeCP2 and CREB in BDNF transcription[52], and an additional function of MeCP2 other than transcriptional regulation, has also been indicated[3]. Recent findings demonstrated a novel epigenetic regulation in BDNF exon IX. Gadd45b, a neural immediate early gene, promotes activity-dependent demethylation in the BDNF exon IX promoter region[53] (Figure 1). Considering that electric stimulation-induced BDNF transcription was dramatically reduced in Gadd45b knock-out mice and that Gadd45b interacts and demethylates the promoter region of BDNF exon IX encoding pre-pro-BDNF[53], a gating function of Gadd45b in neuronal activity-dependent BDNF gene transcription was indicated.

**BDNF TRANSPORT AND SECRETION**

The secretion process of neurotrophins involves either the constitutive or regulated pathway, depending on whether secretion occurs spontaneously or in response to neuronal activity, respectively. Unlike other neurotrophins including NGF and NT-3 that are mainly secreted by the constitutive pathway, BDNF seems to be preferentially sorted into the regulated pathway[54-56]. As described above, the 32 kDa precursor form of BDNF (pre-pro-BDNF) is translated at the rough endoplasmic reticulum (ER) and then proteolytically cleaved to generate the 13 kDa mature form of BDNF. The pre-pro-BDNF is conveyed to the Golgi apparatus and sorted into the membrane stacks of the trans-Golgi network (TGN) where BDNF-containing dense core vesicles (DCVs) bud off. The pro-region of BDNF is implicated in the sorting step of BDNF into secretory vesicles[57,58]. A single nucleotide polymorphism (SNP) at nucleotide 196 in the pro-region of the human BDNF gene that produces an amino acid substitution from valine to methionine (val66met) has a negative effect on the sorting of BDNF into vesicles[57]. The BDNF pro-region also binds to the lipid-raft-associated sorting receptor carboxypeptidase E (CPE) in the TGN, which is an important step for sorting into secretory vesicles[58]. Furthermore, a trans-membrane protein sortilin which mainly resides in the membrane of the Golgi apparatus interacts with the pro-region of BDNF and regulates its sorting. BDNF vesicular sorting was impaired in pheochromocytoma PC12 cells that express the luminal domain sortilin lacking the transmembrane and cytoplasmic domains[59].

BDNF-containing vesicles are transported to secretion sites by motor protein complexes in polarized neurons, although the subcellular localization of BDNF secretion sites in neurons of the adult CNS is still controversial. Transport and secretion of BDNF-containing vesicles into axons and dendrites have been observed in cultured cortical and hippocampal neurons by visualization using exogenously transfected fluorescent protein-tagged BDNF[56,60,61], while knock-in mice expressing Myc-tagged BDNF showed specific localization of BDNF-containing vesicles at presynaptic terminals in the adult (8-wk-old) hippocampus[62]. Intriguingly, the Golgi apparatus present in dendrites was revealed in cultured hippocampal neurons and adult rat hippocampus, with fluorescent protein-tagged BDNF localized to the dendritic Golgi, indicating a local BDNF secretory pathway as well as local translation in dendrites[63,64]. Although BDNF transport properties are still not fully elucidated, bidirectional (anterograde and retrograde) trafficking of BDNF-containing vesicles in axons and dendrites have been reported in cultured neurons[56,65,66]. Furthermore, the anterograde BDNF vesicle transport is microtubule-based with a motor protein kinesin and a coordinator dynactin[13,66]. Several important studies revealed that huntingtin, a polyglutamine-containing protein associated with Huntington disease (HD), and CPE are also involved in the motor protein complex for BDNF-containing vesicle transport and affect properties such as velocity and direction[13,14,65,66].

Evidence suggests that BDNF can be secreted from the cell soma, axon and dendrites of cultured cortical and hippocampal neurons in a neuronal activity (depolarization)-dependent manner[67,68] (Figure 2). Lessmann *et al*[68] clearly showed that activity-dependent BDNF secretion requires Ca2+ influx *via* ionotropic glutamate receptors or L-type VGCC and subsequent amplification of the initial Ca2+ elevation through Ca2+-induced Ca2+ release from internal stores (the endoplasmic reticulum) *via* ryanodine receptors. Activation of Trk receptors or Na+ channels, on the other hand, is not directly associated with BDNF secretion[68-70]. They further revealed that activation of both CaMKII and PKA were also required for secretion[67,70] (Figure 2). Considering the shared signaling pathways between the activity-dependent secretion and transcription of BDNF, decreased BDNF levels after secretion may be restored immediately with simultaneous induction of BDNF transcription. Although molecular mechanisms underlying the vesicle fusion step in BDNF secretion remain unclear, two proteins are suggested to regulate this step: Synaptotagmin IV and Ca2+-dependent activator protein for secretion 2 (CAPS2). Synaptotagmin IV, a soluble NSF attachment protein receptor (SNARE) complex binding protein localized to BDNF containing vesicles, negatively regulates BDNF secretion at both axons and dendrites in hippocampal neurons[71]. It was also reported that CAPS2, a DCV-associated protein, enhanced activity-dependent BDNF secretion efficiency[72,73]. However, it is still unclear whether BDNF-containing vesicles use SNARE-dependent membrane fusion similar to synaptic vesicle exocytosis.

It is a matter of continuous debate where and how pre-pro-BDNF is converted to the mature form of BDNF in the CNS. It was previously concluded that pro-neurotrophins are cleaved by proteases such as furin and pro-protein convertases (PCs) in the trans-Golgi network (TGN) or in DCVs prior to secretion[74]. Several recent studies, however, showed that hippocampal neurons secreted a considerable amount of pro-BDNF that was subsequently processed extracellularly to mature-BDNF by plasmin or matrix metalloproteinases (MMPs)[6,75]. More recently, immediate intracellular conversion of pro-BDNF to mature-BDNF along with co-localization of the cleaved pro-peptide region and mature-BDNF in secretory vesicles in hippocampal neurons were confirmed[62,76]. Resolving the discrepancy of whether neurons secrete pro-BDNF is a very important issue because pro-BDNF preferentially binds to p75NTR rather than TrkB, which in turn causes cell death or synaptic depression in neurons[77,78]. Where pro-neurotrophin cleavage takes place and which proteinases participate in the process might be dependent upon the developmental stage of neurons or the location of BDNF translation (the cell soma or dendrites)[79].

**PHYSIOLOGICAL ROLES OF BDNF IN THE CNS**

Neurons exhibit several distinct features such as a polarized structure, inter-connected circuits, and electrical activity. Many studies have revealed a variety of BDNF functions associated with these features in the developing and mature brain. BDNF acts as a neurite outgrowth and elongation factor, pro-survival factor, and synaptic regulator in the CNS. BDNF promotes axon initiation through two distinct signaling pathways. BDNF induces TrkB-dependent local elevation and stabilization of cAMP/PKA activity that are essential for axon initiation in undifferentiated neurites of hippocampal neurons[80,81]. Furthermore, BDNF/TrkB-induced Akt phosphorylation reduces GSK-3 activation which in turn decreases production of the active form of collapsin response mediator protein-2 (CRMP-2) that plays a critical role in microtubule assembly during axon elongation and branching in rat hippocampal neurons[82,83]. BDNF also promotes axon elongation and branching of sensory neurons both *in vitro* and *in vivo*[83,84]. A BDNF concentration gradient produced by a BDNF-containing micropipette demonstrated an attractive turning effect on the axonal growth cone in cultured *Xenopus* spinal neurons[83,84]. Interestingly, application of specific inhibitors for cAMP or PKA resulted in repulsive turning in the same BDNF gradient, indicating the critical role of cAMP levels to determine the growth cone’s response between attraction and repulsion to the same BDNF gradient[83]. A comprehensive study on BDNF function in dendritic growth done by Wirth *et al*[85]revealed that overexpressed BDNF affected pyramidal cells by increasing length and number of apical dendritic segments in layer VI, and basal dendrites in layer V in rat cortical slice cultures. It is important that such BDNF-promoted dendritogenesis and dendrite growth were observed only in BDNF-overexpressed neurons themselves, suggesting the autocrine action of BDNF[85]. Studies using primary cultured neurons have revealed the importance of MAP kinase and PI3 kinase activation *via* TrkB phosphorylation to promote BDNF-dependent dendritic growth[86,87]. It is also important to note that acute elevation in BDNF concentration promotes total growth of dendrites and the number of primary dendrites while gradual BDNF elevation increases branching number[88].

BDNF also plays a role in synapse formation and stabilization[89]. TrkB knockout mice showed a significant decline in the number of hippocampal synaptic structures[90]. TrkB conditional-mutant mice in which TrkB is deleted in the cerebellum resulted in a reduction of inhibitory synapses[90]. BDNF as a regulator of synaptogenesis *in vivo* was also confirmed in *Xenopus* optic axons[91]. Using the time-lapse imaging technique with GFP-tagged synaptobrevin II as a marker for functional synapses, BDNF-induced retinal ganglion cell axon arborization and synaptogenesis were shown[91]. Furthermore, neutralization of endogenous BDNF by function-blocking antibodies for BDNF rapidly (within 2 h) dismantled pre-existing GFP-synaptobrevin clusters, suggesting its importance in synaptic stabilization[92]. Exogenously applied BDNF induced functional excitatory and inhibitory synapse formation in cultured rat hippocampal neurons[93] and increased excitatory synapse numbers in rat hippocampal slices[94]. On the other hand, there are lines of evidence showing synaptogenic function of BDNF and TrkB in inhibitory GABAergic connections in the visual cortex[95-97], cerebellum[98], organotypic slice cultures of the rat hippocampus[99] and organotypic cerebellar cultures of mice[100]. BDNF serves as an important modulator for synaptic connections in mature neuronal circuits as well as in developing neuronal circuits. BDNF modulates synaptic efficacy and synaptic plasticity such as long-term potentiation (LTP) and long-term depression (LTD) in the developed CNS (for reviews, see[3,101,102]). For example, acute and chronic application of exogenous BDNF potentiates synaptic efficacy by increasing glutamate transmission in rat brain slices of the hippocampus[103], visual cortex[104], and hippocampal dissociated cultures[105,106]. Modulation of NMDA receptor function[107,108] and ion channels including Nav[109], Kv1.3[110], and TRPC3 channels[111] by BDNF contributes to enhancement of excitatory synaptic efficacy. BDNF also promotes spine growth[112,113] and membrane insertion of NMDA[114] and AMPA[115] receptors at the postsynaptic cites of excitatory synapses. Contrary to its predominantly enhancing action on excitatory synapses, BDNF has been reported to modulate the efficacy of GABAergic synapse transmission both presynaptically and postsynaptically in a bi-directional manner. Presynaptic GABA transmission was suppressed by acute BDNF application in hippocampal slices[116] as well as chronic application in hippocampal cultures[117], while chronic BDNF in cultured hippocampal neurons potentiates presynaptic GABA transmission[118]. BDNF shows a bi-directional modulation also on postsynaptic GABAA receptor function. BDNF potentiated[119] and depressed[120,121] GABAergic postsynaptic currents through modulating GABAA receptor functions and regulating membrane insertion of GABAA receptors. Interestingly, BDNF decreased and increased inhibitory postsynaptic currents (IPSCs) when recorded from excitatory and inhibitory neurons, respectively[122]. Furthermore, IPSCs amplitude was increased by acute BDNF treatment in hippocampal slices obtained from postnatal day 6 rats whereas the opposite effect was observed in slices from postnatal day 14 rats[123]. These data indicate the complicated function of BDNF, especially in the modulation of basic properties of developed GABAergic synapses, depending on the region in the brain, stage of maturity, and duration of exposure to BDNF.

It has been frequently reported that synaptic BDNF is involved in LTP and LTD. LTP was first identified in the rat hippocampus as a long-lasting activity-dependent synaptic modification[124,125], and it is the leading hypothesis of the mechanism underlying experience-dependent learning and memory. Important roles of BDNF/TrkB signaling in specific high-frequency electrical stimuli (tetanus or Theta burst stimulation)-induced LTP in brain slices prepared from the hippocampus and cortex have been shown (for reviews, see[102,126]). A severe impairment in hippocampal LTP was confirmed in independent lines of BDNF knockout and heterozygous mice[127]. Interestingly, in heterozygous mice in which BDNF expression in the hippocampus is suppressed to approximately 60% of wild type levels, the same degree of impairment was found in LTP as that of knockout mice. Furthermore, supplementation of exogenous BDNF rescued this impairment, suggesting that BDNF plays a critical role in hippocampal LTP and a threshold level of BDNF is essential to assure LTP induction[128]. Of note, acute hippocampus-specific deletion of the BDNF gene in adult mice showed impaired novel object recognition and spatial learning in the Morris water maze[129]. These mice also demonstrated reduced extinction of conditioned fear in spite of normal acquisition and expression fear, suggesting a critical role for BDNF in hippocampal-dependent cognitive function and memory extinction[129]. TrkB knockout mice also exhibited impaired hippocampal LTP, illustrating the importance of TrkB in hippocampal-dependent learning involved in spatial memory tasks[130]. Mutant TrkB knock-in mice carrying a point mutation in the kinase domain of TrkB demonstrated that PLCγ-dependent activation of CREB and CaMKIV phosphorylation are critical factors for BDNF/TrkB-dependent hippocampal LTP[131]. Recently, mammalian target of rapamycin (mTOR) was also identified as a contributor to BDNF/TrkB-dependent hippocampal LTP[132]. Considering that PI3K and Akt are the upstream regulators of mTOR, the PI3K–AKT–mTOR pathway is thought to play a significant role in BDNF-dependent LTP. The PI3K–AKT pathway was also shown to enhance dendritic transport of PSD-95 to postsynaptic sites depending on BDNF/TrkB signaling[113], suggesting its involvement in persistent structural changes of spines after LTP induction. In contrast to mature BDNF, pro-BDNF mainly plays a role in LTD which is induced by low frequency stimulation (LFS). It has been reported that pro-BDNF enhanced NMDA receptor (NR2B)-dependent LTD in the hippocampus through p75NTR activation[78]. Application of pro-BDNF facilitated NR2B-mediated hippocampal LTD only in the wild type, but not in p75NTR knockout mice[78]. Interestingly, other forms of synaptic plasticity such as NMDA receptor-dependent LTP and NMDA receptor-independent LTD were intact in p75NTR knockout mice[78], suggesting a specific role of pro-BDNF in hippocampal LTD. Considering that p75NTR activation negatively affects dendrite complexity and spine density in hippocampal neurons[133], secreted pro-BDNF, which escapes processing by proteinases, modulates neurite morphology and synaptic plasticity in the opposite way as mature BDNF. Taken together, BDNF is deeply associated with neuronal connectivity through modulating the development of neural circuitry and regulating synaptic efficacy throughout the CNS. Therefore, impairment of BDNF function in the developing and mature brain is implicated in many psychiatric and neurodegenerative diseases.

**CRITICAL BDNF GENE POLYMORPHISM**

A critical non-synonymous single-nucleotide polymorphism (SNP) in the human BDNF gene was first reported in 2003[57], involving an amino acid substitution at valine 66 to methionine (Val66Met)[57]. The BDNF Val66Met polymorphism predominantly affects the sorting process of synthesized BDNF into secretory vesicles[57], resulting in reduction in activity-dependent BDNF secretion[12,57]. Inconsistent with critical BDNF roles in hippocampal LTP, met allele carriers (BDNFmet carriers) showed impaired performance in episodic memory[57,134], verbal memory[135], and cognitive performance[136]. However, it is still controversial whether carrying the met allele causes significant reduction in human hippocampal volume despite the essential roles of BDNF in neurite development[12,137]. A mouse model of the polymorphism BDNFmet/met knock-in mice showed an approximately 15% reduction in hippocampal volume and dendritic arbor complexity[138]. Cultured neurons from BDNFmet/met knock-in mice exhibited normal levels of total BDNF protein but significantly reduced amounts of activity-dependent secretion of BDNF[138]. Interestingly, the BDNFmet/met knock-in mice showed anxiety-related behaviors that did not improve with chronic antidepressant fluoxetine treatment[138]. Detailed electrophysiological analysis of hippocampal slices of BDNFmet/met knock-in mice revealed normal basal glutamatergic transmission but reduced NMDA receptor-mediated current and NMDA receptor-dependent LTP[139]. It is clear that further investigation of BDNF transport and secretion processes are important for more detailed understanding of the neurotrophin and for the development of BDNF-based therapy for patients with brain-related diseases.

**IMPLICATION OF BDNF IN BRAIN DISEASES**

BDNF has been implicated in multiple brain-related diseases, as it plays a critical role in neuronal development, survival, and synaptic function. Although studies show involvement of BDNF in the pathophysiology of multiple brain-related illnesses such as bipolar disorder[140], Parkinson’s disease[140], stroke, epilepsy[141], eating disorders[142], and substance use[142], we review four neuropsychiatric illnesses associated with BDNF dysfunction.

**ALZHEIMER’S DISEASE**

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder with noticeable impairment of cognitive function. Patients with AD show progressive loss of synapses and neurons especially in the entorhinal cortex and hippocampus, which causes a loss of their ability to acquire new memories[11,143-145]. A wide range of evidence exists due to brain cohort differences[146], though decreased expression levels of BDNF protein and mRNA have been consistently reported in the hippocampus and cortex of individuals with AD[147-151] as well as in serum[152] (Table 1). Furthermore, firm conclusions regarding involvement of the Val66Met polymorphism on disease onset or progression of AD have not been made (for review, see[140]). On the other hand, Nagahara *et al*[153] recently reported that BDNF gene delivery to the entorhinal cortex ameliorated entorhinal cortical and hippocampal neuronal degeneration in a mouse model of AD. Mice in this model expressed the human amyloid precursor protein (APP) with mutations and exhibited AD-like pathology such as cortical plaques, progressive cell loss in the entorhinal cortex and cognitive decline by 6–7 mo after birth[153,154]. Direct injection of lentiviral vector constitutively expressing BDNF into the entorhinal cortex of the mice after disease onset reversed synapse loss in both the entorhinal cortex and hippocampus, and restored learning and memory deficits[153]. Such BDNF gene delivery was similarly effective to the reduced memory function in normally aged (24-mo-old) rats and primates[153]. Because the entorhinal cortex is a primary input to the hippocampus, the rescued synaptic loss in the hippocampus of these model animals could be attributed to BDNF transport from the cortical region. Other AD mouse models with amyloid-β (Aβ) overproduction caused by APP mutations exhibited significant reduction in cortical BDNF mRNA[155]. Hippocampal BDNF protein is reduced in the 5XFAD transgenic mice expressing five familial AD (FAD) mutant forms of human APP, with memory deficits rescued by a specific TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), without affecting endogenous BDNF levels[156]. Furthermore, neural stem cell (NSC) transplantation also improved cognitive function in AD model mice via BDNF secreted by NSC[157]. BDNF-based therapy is increasingly expected to ameliorate the symptoms of AD.

**HUNTINGTON DISEASE**

Huntington’s disease (HD) is a neurodegenerative and autosomal dominant disease caused by repeats of the CAG trinucleotide in the huntingtin (htt) gene, which produces abnormal htt proteins with polyglutamine expansion (polyQ). Degeneration of striatal neurons is thought to induce progressive psychiatric, cognitive and motor dysfunction[158]. Possible link between HD and BDNF function has been reported. Given that substantial levels of BDNF protein are detectable in adult rodent striatum while TrkB mRNA, but not BDNF mRNA, is present along with the fact that cortical neurons projecting to the striatum contain high levels of BDNF mRNA, most striatal BDNF is anterogradely transported from the cortex[159]. It was revealed that wild-type htt but not mutant (polyQ) htt stimulated transcription from BDNF exon II in the cerebral cortex[160,161]. Postmortem studies have revealed reduced BDNF mRNA and protein levels in the cortex[162,163], caudate-putamen[163,164], striatum[163], cerebellum[163], and substantia nigra[163] in patients with HD. Decreased serum BDNF levels in patients was also reported[165]. The mouse models of HD expressing exon 1 of the human HD gene with expanded polyQ region recapitulate many of the features of human HD such as progressive behavioral deficit, impaired motor functions, cognitive decline, and premature death[166-169]. Reduced expression of BDNF was confirmed in the cortex[166,167] and striatum[168,169] of three HD mouse models (R6/1, R6/2, and YAC128). The antidepressant sertraline increased BDNF protein levels in the hippocampus and striatum, improving lifespan and motor performance, and ameliorated brain atrophy in R6/2 HD mice[170]. Genetically overexpressed BDNF in the cerebral cortex and striatum of YAC128 HD mice alleviated loss of striatal neurons and motor dysfunction, and improved procedural learning[168]. BDNF overexpression in the striatum improved cortico-striatal connectivity and motor function in R6/2 HD mice[167]. Furthermore, 7,8-DHF and its derivative 4’-dimethylamino-7,8- dihydroxyflavone (4’-DMA-7,8-DHF) extended survival, ameliorated brain atrophy, and improved motor deficits in N171-82Q HD mice[171]. Importantly, forebrain-specific BDNF-knock-out mice (Emx-BDNF KO mice) show a similar phenotype to that observed in the mouse models of HD[172,173]. In contrast to evidence suggesting involvement of BDNF in the pathophysiology of HD, no association between the Val66Met polymorphism of the BDNF gene and onset/progression of HD has been reported[174-178].

 Gauthier *et al*[13] have unveiled an important htt function in BDNF transport. Mutant htt reduced post-Golgi microtubule-based axonal transport velocity of BDNF-containing vesicles while wild-type htt accelerated transport velocity in cultured cortical neurons[13]. These findings suggest that mutations in htt lead to decreased amounts of BDNF in the striatum by inhibiting both BDNF transcription and axonal transport of BDNF-containing vesicles in cortical neurons. Furthermore, the direction of transport was regulated by phosphorylation of htt at serine 421[14]. Phosphorylated htt recruited motor protein kinesin-1 to BDNF-containing vesicles to facilitate anterograde transport, though wild-type htt enhances both anterograde and retrograde transport efficiency in cortical neurons. In contrast, retrograde transport was increased in the absence of htt phosphorylation at the serine 421 site[14]. Interestingly, mutant htt impairs the post-Golgi transport only in val-BDNF-containing vesicles but not in met-BDNF, which in turn produces a reduction in the amount of activity-dependent secretion of val-BDNF in cell lines[179]. Severely reduced BDNF levels in R6/1 HD mice hippocampus and striatum were rescued by environmental enrichment[169]. The enrichment, consisting of small cardboard boxes, small open wooden boxes, cylindrical cardboard tunnels, and folded sheets of paper prevented body weight loss and ameliorated motor symptoms of the mice[169]. Considering that the striatum itself does not produce BDNF and receives BDNF supply from the cortex, such enrichment may compensate by attenuating the mutant htt-induced impairment of anterograde transport of BDNF to the striatum[169,170]. Given the functional interaction between BDNF and htt, exogenous supplementation of BDNF or TrkB agonists to the striatum would be the primary choice for the treatment of HD patients.

**DEPRESSION**

Several lines of evidence implicate BDNF in the pathophysiology of psychiatric disorders[10-12,180]. Specifically, reduced BDNF expression levels and impaired BDNF function have been reported in patients with depression and schizophrenia[181-184]. Reduced BDNF[185-187] or TrkB[188] levels in the prefrontal cortex[185,186,188], hippocampus[185,186], amygdala[187], and serum[189-191] have been demonstrated in patients with depression, especially in suicide victims[185,186,189]. Considering that BDNF protein levels were unchanged in hippocampal and cortical tissue of suicide subjects who had been treated with antidepressants[186], increased levels of BDNF in these brain regions may be facilitated by treatment with antidepressants. Decreased serum BDNF levels have been also reported in patients with depression[189-191], which was recovered by antidepressant drug treatment[191-193]. Increased expression of BDNF or TrkB mRNA in the cerebellum[194] was also shown after chronic antidepressant treatment in subjects with depression. Decreased BDNF and TrkB expression levels are also evident in rodent models of depression. A variety of stressors on rodents such as social defeat[195], restraint (immobilization)[196,197], maternal deprivation[198], and glucocorticoid administration[196,199-201] can reduce BDNF and TrkB expression levels in the hippocampus, cortex, and amygdala. In the normal rat brain, hippocampal and cortical BDNF/TrkB levels were increased after administration of tricyclic antidepressants (TCA; including imipramine, desipramine)[202-204], selective serotonin reuptake inhibitors (SSRI; fluoxetine, paroxetine, sertraline)[202,204-206], noradrenergic and specific serotonergic antidepressants (NaSSA; mirtazapine, mianserin)[202,207], and monoamine oxidase inhibitors (MAOIs; tranylcypromine)[202-204]. Electroconvulsive seizures also significantly induced BDNF expression in the cortex[202,208] and hippocampus[202,209-211]. 7,8-DHF, a specific TrkB agonist, and its -methylated metabolites showed an antidepressant-like effect in the forced swimming and tail suspension tests[212]. Of note, direct BDNF infusion into the rat midbrain induced antidepressant-like effects[213]. Interestingly, TrkB phosphorylation was also increased by antidepressants in the rat brain[214]. An antidepressant imipramine, however, induced TrkB phosphorylation even in the conditional BDNF knock-out mice, suggesting the antidepressant-induced TrkB activation might be BDNF-independent[215]. Despite compelling evidence of BDNF contribution to depression onset and symptoms, meta-analysis with inconsistent results from genetic association studies of the BDNF val66met polymorphism revealed no significant association between the val66met polymorphism and depression[216]. It must be noted, however, that the polymorphism may affect the development of depression more in men than in women[216].

Chronic stress-induced hypothalamic pituitary-adrenal (HPA) axis abnormalities result in increased serum levels of glucocorticoids that are implicated in the pathogenesis of depression[10,217,218]. The HPA axis is an important endocrinological coping mechanism against stressful stimuli that includes release of hormones such as corticotropin-releasing hormone (CRH) from the paraventricular nucleus (PVN), CRH-trigged adrenocorticotropic hormone (ACTH) from the anterior pituitary, and ACTH-induced glucocorticoids from the adrenal glands. We recently reported that the glucocorticoid receptor (GR), which has both genomic and non-genomic properties in cortical neurons, requires TrkB interaction for full activation of the BDNF-induced PLCγ pathway[219]. Chronic treatment with glucocorticoids decreased GR protein levels, and inhibited TrkB-GR interaction and resultant BDNF-induced glutamate release *via* the PLCγ pathway[219]. On the other hand, Jeanneteau *et al*[220] showed TrkB activation by acute administration of glucocorticoids in cortical neurons. The activation of TrkB by glucocorticoids promoted neuronal survival through the transcriptional function of GR and Akt signaling pathway activation[220]. They also revealed that BDNF/TrkB signaling regulates GR transcriptional activity by stimulating GR phosphorylation at S155 and S287[221,222]. These results suggest a possible involvement of the impaired reciprocal interaction between BDNF and the HPA axis in the pathogenesis of depressive disorders. Taken together, BDNF-based therapy for depressed patients could target GR function or the direct activation of TrkB[12].

**SCHIZOPHRENIA**

Approximately 1% of the world population is affected by schizophrenia. This psychiatric condition manifests in three major ways: Positive symptoms (hallucinations, delusions, thought and movement disorders), negative symptoms (flat affect, lack of pleasure and ability to begin and sustain planned activities), and cognitive symptoms (impaired ability to understand and use information, and problems with "working memory”)[223]. Several brain regions have been implicated in the pathophysiology of this illness. Studies on postmortem brain tissue of schizophrenia patients demonstrates that the overall number of neurons in the prefrontal cortex is not decreased[224]. However, reduced synaptophysin (presynaptic protein) immunoreactivity and dendritic spine density of pyramidal cells were observed in the cortex[225,226], suggesting synaptic dysfunction in the pathogenesis of the disease. Because symptoms usually start between ages 16 and 30 with only rare cases reported after age 45[227], deficits in synaptic maturation and overall brain development may be heavily involved in disease onset. Expression levels of BDNF or TrkB have been investigated in brains of patients with schizophrenia. Whether or not BDNF levels are altered in brain tissue or serum of patients with schizophrenia is a controversial topic[184,228,229]. Some postmortem studies demonstrated elevated BDNF protein levels in the hippocampal and cortical tissue in schizophrenic patients[230,231], while decreased BDNF levels have also been shown in these brain regions[231-234] (Table 1). Reduced BDNF mRNA and protein levels in serum of patients with schizophrenia have been consistently reported (Table 1). There are some reports showing that clozapine treatment increased serum BDNF mRNA levels in patients[235,236]. A meta-analysis examining blood BDNF levels in schizophrenia found a moderate effect of reduced BDNF in patents with schizophrenia compared with controls[237]. Furthermore, val/met and met/met BDNF genotypes were reported in a meta-analysis to increase the risk of schizophrenia[142]. Decreased BDNF mRNA and protein levels have also been confirmed in animal models of schizophrenia induced by phencyclidine (PCP)[238], MK-801[239] or ibotenic acid[240]. In contrast to human patients, antipsychotic administration in rodents significantly reduces BDNF expression levels (Table 1). Second-generation antipsychotics such as risperidone (RISP) and olanzapine (OLZ), in addition to first-generation antipsychotics such as haloperidol (HAL) and chlorpromazine (CPZ), all tend to reduce BDNF protein levels in the rat cortex, hippocampus, and striatum[241-243] (Table 1). Although it is challenging to approach the molecular mechanisms underlying the pathophysiology of schizophrenia, PCP, a psychomimetic drug, is known to produce beneficial animal and cellular models for schizophrenia. PCP acts as a non-competitive NMDA receptor blocker and generates schizophrenia-like behavioral changes in humans and rodents[244,245]. Interestingly, sub-chronic PCP (2 mg/kg, *i.p.* twice daily for 7 days followed by 6 wk drug-free) administration decreased BDNF mRNA levels in many brain regions including the cortical, hippocampal, and amygdaloid regions in adult rats[238], while higher doses of PCP (10 mg/kg, *i.p.* for 14 d) increased BDNF levels in the hippocampus and entorhinal cortex of rat pups[246]. We recently demonstrated that PCP suppressed the activity-dependent secretion of BDNF in cultured cortical neurons through blockade of Ca2+ influx *via* NMDA receptors[15] (Figure 3). Decreased BDNF secretion subsequently caused a reduction in the activation of TrkB-dependent signaling pathways and resultant synaptic loss in cortical neurons[15], which is consistent with the observation that patients demonstrate reduced cortical synaptic structure[225-227]. Because of the multifactorial etiology of schizophrenia, whether the BDNF-based approach would be effective or not is unclear in this disease. Ultimately, the multiple, essential roles of BDNF in synaptic function, however, could influence future therapy for these patients.

**CONCLUSION**

Many efforts are being dedicated to understanding the intracellular processes of BDNF to develop BDNF-based effective treatments for the brain-related diseases. Although brain diseases are associated with an overall decrease in BDNF function, varying BDNF levels in specific brain regions may affect symptom attenuation. As BDNF does not cross the blood-brain barrier (BBB), researchers are challenged to develop BDNF gene or protein delivery methods to the CNS[11]. Molecules that increase BDNF or TrkB expression levels, TrkB phosphorylation or membrane insertion, or conversion from pro-BDNF to mature BDNF are important and novel treatment options[12]. Even if BDNF itself is not the main gene responsible for the particular brain disease, BDNF-based treatments may provide valuable symptom relief. It is also critical to elucidate the basic molecular mechanisms of BDNF expression, transport, and secretion so that new therapeutic approaches may be developed to treat these debilitating neuropsychiatric conditions.

**REFERENCES**

1 **Barde YA**, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. *EMBO J* 1982; **1**: 549-553 [PMID: 7188352]

2 **Cohen S**, Levi-Montalcini R, Hamburger V. A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180. *Proc Natl Acad Sci U S A* 1954; **40**: 1014-1018 [PMID: 16589582]

3 **Park H**, Poo MM. Neurotrophin regulation of neural circuit development and function. *Nat Rev Neurosci* 2013; **14**: 7-23 [PMID: 23254191 DOI: 10.1038/nrn3379]

4 **Lu B**. Pro-region of neurotrophins: role in synaptic modulation. *Neuron* 2003; **39**: 735-738 [PMID: 12948441]

5 **Chao MV**. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* 2003; **4**: 299-309 [PMID: 12671646 DOI: doi: 10.1038/nrn3379]

6 **Lu B**, Pang PT, Woo NH. The yin and yang of neurotrophin action. *Nat Rev Neurosci* 2005; **6**: 603-614 [PMID: 16062169 DOI: 10.1038/nrn1726]

7 **Huang EJ**, Reichardt LF. Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 2003; **72**: 609-642 [PMID: 12676795 DOI: 10.1146/annurev.biochem.72.121801.161629]

8 **Minichiello L**. TrkB signalling pathways in LTP and learning. *Nat Rev Neurosci* 2009; **10**: 850-860 [PMID: 19927149 DOI: 10.1038/nrn2738]

9 **Russo SJ**, Mazei-Robison MS, Ables JL, Nestler EJ. Neurotrophic factors and structural plasticity in addiction. *Neuropharmacology* 2009; **56 Suppl 1**: 73-82 [PMID: 18647613 DOI: 10.1016/j.neuropharm]

10 **Numakawa T**, Adachi N, Richards M, Chiba S, Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. *Neuroscience* 2013; **239**: 157-172 [PMID: 23069755 DOI: 10.1016/j.neuroscience.2012.09.073]

11 **Nagahara AH**, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. *Nat Rev Drug Discov* 2011; **10**: 209-219 [PMID: 21358740 DOI: 10.1038/nrd3366]

12 **Lu B**, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. *Nat Rev Neurosci* 2013; **14**: 401-416 [PMID: 23674053 DOI: 10.1038/nrn3505]

13 **Gauthier LR**, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. *Cell* 2004; **118**: 127-138 [PMID: 15242649]

14 **Colin E**, Zala D, Liot G, Rangone H, Borrell-Pagès M, Li XJ, Saudou F, Humbert S. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. *EMBO J* 2008; **27**: 2124-2134 [PMID: 18615096 DOI: 10.1038/emboj.2008.133]

15 **Adachi N**, Numakawa T, Kumamaru E, Itami C, Chiba S, Iijima Y, Richards M, Katoh-Semba R, Kunugi H. Phencyclidine-induced decrease of synaptic connectivity via inhibition of BDNF secretion in cultured cortical neurons. *Cereb Cortex* 2013; **23**: 847-858 [PMID: 22467667 DOI: 10.1093/cercor/bhs074]

16 **Ernfors P**, Wetmore C, Olson L, Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. *Neuron* 1990; **5**: 511-526 [PMID: 2206535]

17 **Hofer M**, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. *EMBO J* 1990; **9**: 2459-2464 [PMID: 2369898]

18 **Conner JM**, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. *J Neurosci* 1997; **17**: 2295-2313 [PMID: 9065491]

19 **Yan Q**, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, Bennett L, Welcher AA. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. *Neuroscience* 1997; **78**: 431-448 [PMID: 9145800]

20 **Katoh-Semba R**, Takeuchi IK, Semba R, Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. *J Neurochem* 1997; **69**: 34-42 [PMID: 9202291 DOI: 10.1046/j.1471-4159.1997.69010034.x]

21 **Gorba T**, Klostermann O, Wahle P. Development of neuronal activity and activity-dependent expression of brain-derived neurotrophic factor mRNA in organotypic cultures of rat visual cortex. *Cereb Cortex* 1999; **9**: 864-877 [PMID: 10601005 DOI: 10.1093/cercor/9.8.864]

22 **Patz S**, Wahle P. Developmental changes of neurotrophin mRNA expression in the layers of rat visual cortex. *Eur J Neurosci* 2006; **24**: 2453-2460 [PMID: 17100834 DOI: 10.1111/j.1460-9568.2006.05126.x]

23 **Liu QR**, Lu L, Zhu XG, Gong JP, Shaham Y, Uhl GR. Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. *Brain Res* 2006; **1067**: 1-12 [PMID: 16376315]

24 **Aid T**, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. *J Neurosci Res* 2007; **85**: 525-535 [PMID: 17149751 DOI: 10.1002/jnr.21139]

25 **Pruunsild P**, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. *Genomics* 2007; **90**: 397-406 [PMID: 17629449 DOI: 10.1016/j.ygeno.2007.05.004]

26 **Timmusk T**, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. *Neuron* 1993; **10**: 475-489 [PMID: 8461137]

27 **An JJ**, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre ER, Jones KR, Feng Y, Lu B, Xu B. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. *Cell* 2008; **134**: 175-187 [PMID: 18614020 DOI: 10.1016/j.cell.2008.05.045]

28 **Lin Y**, Bloodgood BL, Hauser JL, Lapan AD, Koon AC, Kim TK, Hu LS, Malik AN, Greenberg ME. Activity-dependent regulation of inhibitory synapse development by Npas4. *Nature* 2008; **455**: 1198-1204 [PMID: 18815592 DOI: 10.1038/nature07319]

29 **Isackson PJ**, Huntsman MM, Murray KD, Gall CM. BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. *Neuron* 1991; **6**: 937-948 [PMID: 2054188]

30 **Castrén E**, Zafra F, Thoenen H, Lindholm D. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. *Proc Natl Acad Sci U S A* 1992; **89**: 9444-9448 [PMID: 1409655 DOI: 10.1073/pnas.89.20.9444]

31 **Bozzi Y**, Pizzorusso T, Cremisi F, Rossi FM, Barsacchi G, Maffei L. Monocular deprivation decreases the expression of messenger RNA for brain-derived neurotrophic factor in the rat visual cortex. *Neuroscience* 1995; **69**: 1133-1144 [PMID: 8848102]

32 **Rocamora N**, Welker E, Pascual M, Soriano E. Upregulation of BDNF mRNA expression in the barrel cortex of adult mice after sensory stimulation. *J Neurosci* 1996; **16**: 4411-4419 [PMID: 8699252]

33 **Zafra F**, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. *EMBO J* 1990; **9**: 3545-3550 [PMID: 2170117]

34 **Zafra F**, Castrén E, Thoenen H, Lindholm D. Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. *Proc Natl Acad Sci U S A* 1991; **88**: 10037-10041 [PMID: 1658793]

35 **Zafra F**, Lindholm D, Castrén E, Hartikka J, Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. *J Neurosci* 1992; **12**: 4793-4799 [PMID: 1281495]

36 **Tao X**, West AE, Chen WG, Corfas G, Greenberg ME. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. *Neuron* 2002; **33**: 383-395 [PMID: 11832226]

37 **Zheng F**, Zhou X, Luo Y, Xiao H, Wayman G, Wang H. Regulation of brain-derived neurotrophic factor exon IV transcription through calcium responsive elements in cortical neurons. *PLoS One* 2011; **6**: e28441 [PMID: 22174809 DOI: 10.1371/journal.pone.0028441]

38 **Zheng F**, Zhou X, Moon C, Wang H. Regulation of brain-derived neurotrophic factor expression in neurons. *Int J Physiol Pathophysiol Pharmacol* 2012; **4**: 188-200 [PMID: 23320132]

39 **Koppel I**, Timmusk T. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors. *Neuropharmacology* 2013; **75**: 106-115 [PMID: 23916482 DOI: 10.1016/j.neuropharm.2013.07.015]

40 **Hong EJ**, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. *Neuron* 2008; **60**: 610-624 [PMID: 19038219 DOI: 10.1016/j.neuron.2008.09.024]

41 **Chen WG**, West AE, Tao X, Corfas G, Szentirmay MN, Sawadogo M, Vinson C, Greenberg ME. Upstream stimulatory factors are mediators of Ca2+-responsive transcription in neurons. *J Neurosci* 2003; **23**: 2572-2581 [PMID: 12684442]

42 **McDowell KA**, Hutchinson AN, Wong-Goodrich SJ, Presby MM, Su D, Rodriguiz RM, Law KC, Williams CL, Wetsel WC, West AE. Reduced cortical BDNF expression and aberrant memory in Carf knock-out mice. *J Neurosci* 2010; **30**: 7453-7465 [PMID: 20519520 DOI: 10.1523/JNEUROSCI.3997-09.2010]

43 **Jiang X**, Tian F, Du Y, Copeland NG, Jenkins NA, Tessarollo L, Wu X, Pan H, Hu XZ, Xu K, Kenney H, Egan SE, Turley H, Harris AL, Marini AM, Lipsky RH. BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. *J Neurosci* 2008; **28**: 1118-1130 [PMID: 18234890 DOI: 10.1523/JNEUROSCI.2262-07.2008]

44 **Kairisalo M**, Korhonen L, Sepp M, Pruunsild P, Kukkonen JP, Kivinen J, Timmusk T, Blomgren K, Lindholm D. NF-kappaB-dependent regulation of brain-derived neurotrophic factor in hippocampal neurons by X-linked inhibitor of apoptosis protein. *Eur J Neurosci* 2009; **30**: 958-966 [PMID: 19735291 DOI: 10.1111/j.1460-9568.2009.06898.x]

45 **Tabuchi A**, Sakaya H, Kisukeda T, Fushiki H, Tsuda M. Involvement of an upstream stimulatory factor as well as cAMP-responsive element-binding protein in the activation of brain-derived neurotrophic factor gene promoter I. *J Biol Chem* 2002; **277**: 35920-35931 [PMID: 12114522 DOI: 10.1074/jbc.M204784200]

46 **Lubin FD**, Ren Y, Xu X, Anderson AE. Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. *J Neurochem* 2007; **103**: 1381-1395 [PMID: 17727632 DOI: 10.1111/j.1471-4159.2007.04863.x]

47 **Flavell SW**, Kim TK, Gray JM, Harmin DA, Hemberg M, Hong EJ, Markenscoff-Papadimitriou E, Bear DM, Greenberg ME. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. *Neuron* 2008; **60**: 1022-1038 [PMID: 19109909 DOI: 10.1016/j.neuron.2008.11.029]

48 **Koppel I**, Aid-Pavlidis T, Jaanson K, Sepp M, Pruunsild P, Palm K, Timmusk T. Tissue-specific and neural activity-regulated expression of human BDNF gene in BAC transgenic mice. *BMC Neurosci* 2009; **10**: 68 [PMID: 19555478 DOI: 10.1186/1471-2202-10-68]

49 **Pruunsild P**, Sepp M, Orav E, Koppel I, Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. *J Neurosci* 2011; **31**: 3295-3308 [PMID: 21368041 DOI: 10.1523/JNEUROSCI.4540-10.2011]

50 **Chen WG**, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. *Science* 2003; **302**: 885-889 [PMID: 14593183 DOI: 10.1126/science.1086446]

51 **Chang Q**, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron* 2006; **49**: 341-348 [PMID: 16446138]

52 **Chahrour M**, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 2008; **320**: 1224-1229 [PMID: 18511691 DOI: 10.1126/science.1153252]

53 **Ma DK**, Jang MH, Guo JU, Kitabatake Y, Chang ML, Pow-Anpongkul N, Flavell RA, Lu B, Ming GL, Song H. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science* 2009; **323**: 1074-1077 [PMID: 19119186 DOI: 10.1126/science.1166859]

54 **Goodman LJ**, Valverde J, Lim F, Geschwind MD, Federoff HJ, Geller AI, Hefti F. Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. *Mol Cell Neurosci* 1996; **7**: 222-238 [PMID: 8726105]

55 **Farhadi HF**, Mowla SJ, Petrecca K, Morris SJ, Seidah NG, Murphy RA. Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. *J Neurosci* 2000; **20**: 4059-4068 [PMID: 10818141]

56 **Adachi N**, Kohara K, Tsumoto T. Difference in trafficking of brain-derived neurotrophic factor between axons and dendrites of cortical neurons, revealed by live-cell imaging. *BMC Neurosci* 2005; **6**: 42 [PMID: 15969745 DOI: 10.1186/1471-2202-6-42]

57 **Egan MF**, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003; **112**: 257-269 [PMID: 12553913]

58 **Lou H**, Kim SK, Zaitsev E, Snell CR, Lu B, Loh YP. Sorting and activity-dependent secretion of BDNF require interaction of a specific motif with the sorting receptor carboxypeptidase e. *Neuron* 2005; **45**: 245-255 [PMID: 15664176]

59 **Chen ZY**, Ieraci A, Teng H, Dall H, Meng CX, Herrera DG, Nykjaer A, Hempstead BL, Lee FS. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. *J Neurosci* 2005; **25**: 6156-6166 [PMID: 15987945 DOI: 10.1523/JNEUROSCI.1017-05.2005]

60 **Matsuda N**, Lu H, Fukata Y, Noritake J, Gao H, Mukherjee S, Nemoto T, Fukata M, Poo MM. Differential activity-dependent secretion of brain-derived neurotrophic factor from axon and dendrite. *J Neurosci* 2009; **29**: 14185-14198 [PMID: 19906967 DOI: 10.1523/JNEUROSCI.1863-09.2009]

61 **Jakawich SK**, Nasser HB, Strong MJ, McCartney AJ, Perez AS, Rakesh N, Carruthers CJ, Sutton MA. Local presynaptic activity gates homeostatic changes in presynaptic function driven by dendritic BDNF synthesis. *Neuron* 2010; **68**: 1143-1158 [PMID: 21172615 DOI: 10.1016/j.neuron.2010.11.034]

62 **Dieni S**, Matsumoto T, Dekkers M, Rauskolb S, Ionescu MS, Deogracias R, Gundelfinger ED, Kojima M, Nestel S, Frotscher M, Barde YA. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. *J Cell Biol* 2012; **196**: 775-788 [PMID: 22412021 DOI: 10.1083/jcb.201201038]

63 **Horton AC**, Rácz B, Monson EE, Lin AL, Weinberg RJ, Ehlers MD. Polarized secretory trafficking directs cargo for asymmetric dendrite growth and morphogenesis. *Neuron* 2005; **48**: 757-771 [PMID: 16337914]

64 **Horton AC**, Ehlers MD. Dual modes of endoplasmic reticulum-to-Golgi transport in dendrites revealed by live-cell imaging. *J Neurosci* 2003; **23**: 6188-6199 [PMID: 12867502]

65 **Park JJ**, Cawley NX, Loh YP. A bi-directional carboxypeptidase E-driven transport mechanism controls BDNF vesicle homeostasis in hippocampal neurons. *Mol Cell Neurosci* 2008; **39**: 63-73 [PMID: 18573344 DOI: 10.1016/j.mcn.2008.05.016]

66 **Kwinter DM**, Lo K, Mafi P, Silverman MA. Dynactin regulates bidirectional transport of dense-core vesicles in the axon and dendrites of cultured hippocampal neurons. *Neuroscience* 2009; **162**: 1001-1010 [PMID: 19497353 DOI: 10.1016/j.neuroscience.2009.05.038]

67 **Edelmann E**, Lessmann V, Brigadski T. Pre- and postsynaptic twists in BDNF secretion and action in synaptic plasticity. *Neuropharmacology* 2014; **76 Pt C**: 610-627 [PMID: 23791959 DOI: 10.1016/j.neuropharm.2013.05.043]

68 **Lessmann V**, Brigadski T. Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update. *Neurosci Res* 2009; **65**: 11-22 [PMID: 19523993 DOI: 10.1016/j.neures.2009.06.004]

69 **Hartmann M**, Heumann R, Lessmann V. Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. *EMBO J* 2001; **20**: 5887-5897 [PMID: 11689429 DOI: 10.1093/emboj/20.21.5887]

70 **Kolarow R**, Brigadski T, Lessmann V. Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening. *J Neurosci* 2007; **27**: 10350-10364 [PMID: 17898207 DOI: 10.1523/JNEUROSCI.0692-07.2007]

71 **Dean C**, Liu H, Dunning FM, Chang PY, Jackson MB, Chapman ER. Synaptotagmin-IV modulates synaptic function and long-term potentiation by regulating BDNF release. *Nat Neurosci* 2009; **12**: 767-776 [PMID: 19448629 DOI: 10.1038/nn.2315]

72 **Sadakata T**, Furuichi T. Developmentally regulated Ca2+-dependent activator protein for secretion 2 (CAPS2) is involved in BDNF secretion and is associated with autism susceptibility. *Cerebellum* 2009; **8**: 312-322 [PMID: 19238500 DOI: 10.1007/s12311-009-0097-5]

73 **Shinoda Y**, Sadakata T, Nakao K, Katoh-Semba R, Kinameri E, Furuya A, Yanagawa Y, Hirase H, Furuichi T. Calcium-dependent activator protein for secretion 2 (CAPS2) promotes BDNF secretion and is critical for the development of GABAergic interneuron network. *Proc Natl Acad Sci U S A* 2011; **108**: 373-378 [PMID: 21173225 DOI: 10.1073/pnas.1012220108]

74 **Seidah NG**, Benjannet S, Pareek S, Savaria D, Hamelin J, Goulet B, Laliberte J, Lazure C, Chrétien M, Murphy RA. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. *Biochem J* 1996; **314 (Pt 3)**: 951-960 [PMID: 8615794]

75 **Pang PT**, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL, Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. *Science* 2004; **306**: 487-491 [PMID: 15486301 DOI: 10.1126/science.1100135]

76 **Matsumoto T**, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, Barde YA. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. *Nat Neurosci* 2008; **11**: 131-133 [PMID: 18204444 DOI: 10.1038/nn2038]

77 **Lee R**, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. *Science* 2001; **294**: 1945-1948 [PMID: 11729324 DOI: 10.1126/science.1065057]

78 **Woo NH**, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. *Nat Neurosci* 2005; **8**: 1069-1077 [PMID: 16025106 DOI: 10.1038/nn1510]

79 **Barker PA**. Whither proBDNF? *Nat Neurosci* 2009; **12**: 105-106 [PMID: 19172162 DOI: 10.1038/nn0209-105]

80 **Shelly M**, Cancedda L, Lim BK, Popescu AT, Cheng PL, Gao H, Poo MM. Semaphorin3A regulates neuronal polarization by suppressing axon formation and promoting dendrite growth. *Neuron* 2011; **71**: 433-446 [PMID: 21835341 DOI: 10.1016/j.neuron.2011.06.041]

81 **Cheng PL**, Song AH, Wong YH, Wang S, Zhang X, Poo MM. Self-amplifying autocrine actions of BDNF in axon development. *Proc Natl Acad Sci U S A* 2011; **108**: 18430-18435 [PMID: 22025720 DOI: 10.1073/pnas.1115907108]

82 **Yoshimura T**, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell* 2005; **120**: 137-149 [PMID: 15652488 DOI: 10.1016/j.cell.2004.11.012]

83 **Song HJ**, Ming GL, Poo MM. cAMP-induced switching in turning direction of nerve growth cones. *Nature* 1997; **388**: 275-279 [PMID: 9230436]

84 **Cohen-Cory S**, Fraser SE. Effects of brain-derived neurotrophic factor on optic axon branching and remodelling in vivo. *Nature* 1995; **378**: 192-196 [PMID: 7477323 DOI: 10.1038/378192a0]

85 **Wirth MJ**, Brun A, Grabert J, Patz S, Wahle P. Accelerated dendritic development of rat cortical pyramidal cells and interneurons after biolistic transfection with BDNF and NT4/5. *Development* 2003; **130**: 5827-5838 [PMID: 14573511 DOI: 10.1242/dev.00826]

86 **Miller FD**, Kaplan DR. Signaling mechanisms underlying dendrite formation. *Curr Opin Neurobiol* 2003; **13**: 391-398 [PMID: 12850225 DOI: 10.1016/S0959-4388(03)00072-2]

87 **Dijkhuizen PA**, Ghosh A. BDNF regulates primary dendrite formation in cortical neurons via the PI3-kinase and MAP kinase signaling pathways. *J Neurobiol* 2005; **62**: 278-288 [PMID: 15514998 DOI: 10.1002/neu.20100]

88 **Ji Y**, Lu Y, Yang F, Shen W, Tang TT, Feng L, Duan S, Lu B. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. *Nat Neurosci* 2010; **13**: 302-309 [PMID: 20173744 DOI: 10.1038/nn.2505]

89 **Vicario-Abejón C**, Owens D, McKay R, Segal M. Role of neurotrophins in central synapse formation and stabilization. *Nat Rev Neurosci* 2002; **3**: 965-974 [PMID: 12461553 DOI: 10.1038/nrn988]

90 **Martínez A**, Alcántara S, Borrell V, Del Río JA, Blasi J, Otal R, Campos N, Boronat A, Barbacid M, Silos-Santiago I, Soriano E. TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connections. *J Neurosci* 1998; **18**: 7336-7350 [PMID: 9736654]

91 **Alsina B**, Vu T, Cohen-Cory S. Visualizing synapse formation in arborizing optic axons in vivo: dynamics and modulation by BDNF. *Nat Neurosci* 2001; **4**: 1093-1101 [PMID: 11593233 DOI: 10.1038/nn735]

92 **Hu B**, Nikolakopoulou AM, Cohen-Cory S. BDNF stabilizes synapses and maintains the structural complexity of optic axons in vivo. *Development* 2005; **132**: 4285-4298 [PMID: 16141221]

93 **Vicario-Abejón C,** Collin C, McKay RD, Segal M. Neurotrophins induce formation of functional excitatory and inhibitory synapses between cultured hippocampal neurons. *J Neurosci* 1998; **18:** 7256-72571 [PMID: 9736647]

94 **Tyler WJ**, Pozzo-Miller LD. BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. *J Neurosci* 2001; **21**: 4249-4258 [PMID: 11404410]

95 **Huang ZJ**, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF, Maffei L, Tonegawa S. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. *Cell* 1999; **98**: 739-755 [PMID: 10499792 DOI: 10.1016/S0092-8674(00)81509-3]

96 **Kohara K**, Yasuda H, Huang Y, Adachi N, Sohya K, Tsumoto T. A local reduction in cortical GABAergic synapses after a loss of endogenous brain-derived neurotrophic factor, as revealed by single-cell gene knock-out method. *J Neurosci* 2007; **27**: 7234-7244 [PMID: 17611276 DOI: 10.1523/JNEUROSCI.1943-07.2007]

97 **Abidin I**, Eysel UT, Lessmann V, Mittmann T. Impaired GABAergic inhibition in the visual cortex of brain-derived neurotrophic factor heterozygous knockout mice. *J Physiol* 2008; **586**: 1885-1901 [PMID: 18238806 DOI: 10.1113/jphysiol.2007.148627]

98 **Rico B**, Xu B, Reichardt LF. TrkB receptor signaling is required for establishment of GABAergic synapses in the cerebellum. *Nat Neurosci* 2002; **5**: 225-233 [PMID: 11836532 DOI: 10.1038/nn808]

99 **Marty S**, Wehrlé R, Sotelo C. Neuronal activity and brain-derived neurotrophic factor regulate the density of inhibitory synapses in organotypic slice cultures of postnatal hippocampus. *J Neurosci* 2000; **20**: 8087-8095 [PMID: 11050130]

100 **Seil FJ,** Drake-Baumann R. TrkB receptor ligands promote activity-dependent inhibitory synaptogenesis. *J Neurosci* 2000; **20:** 5367-5373 [PMID: 10884321]

101 **Lu Y**, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? *Neurobiol Learn Mem* 2008; **89**: 312-323 [PMID: 17942328 DOI: 10.1016/j.nlm.2007.08.018]

102 **Gottmann K**, Mittmann T, Lessmann V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. *Exp Brain Res* 2009; **199**: 203-234 [PMID: 19777221 DOI: 10.1007/s00221-009-1994-z]

103 **Kang H**, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. *Science* 1995; **267**: 1658-1662 [PMID: 7886457 DOI: 10.1126/science]

104 **Carmignoto G**, Pizzorusso T, Tia S, Vicini S. Brain-derived neurotrophic factor and nerve growth factor potentiate excitatory synaptic transmission in the rat visual cortex. *J Physiol* 1997; **498 (Pt 1)**: 153-164 [PMID: 9023775]

105 **Lessmann V**, Gottmann K, Heumann R. BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurones. *Neuroreport* 1994; **6**: 21-25 [PMID: 7703418]

106 **Levine ES**, Dreyfus CF, Black IB, Plummer MR. Brain-derived neurotrophic factor rapidly enhances synaptic transmission in hippocampal neurons via postsynaptic tyrosine kinase receptors. *Proc Natl Acad Sci U S A* 1995; **92**: 8074-8077 [PMID: 7644540]

107 **Suen PC,** Wu K, Levine ES, Mount HT, Xu JL, Lin SY, Black IB. Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-D-aspartate receptor subunit 1. *Proc Natl Acad Sci U S A* 1997; **94:** 8191-8195 [PMID: 9223337]

108 **Lin SY**, Wu K, Levine ES, Mount HT, Suen PC, Black IB. BDNF acutely increases tyrosine phosphorylation of the NMDA receptor subunit 2B in cortical and hippocampal postsynaptic densities. *Brain Res Mol Brain Res* 1998; **55**: 20-27 [PMID: 9645956 DOI: 10.1016/S0169-328X(97)00349-5]

109 **Lesser SS**, Sherwood NT, Lo DC. Neurotrophins differentially regulate voltage-gated ion channels. *Mol Cell Neurosci* 1997; **10**: 173-183 [PMID: 9532579 DOI: 10.1006/mcne.1997.0656]

110 **Tucker K**, Fadool DA. Neurotrophin modulation of voltage-gated potassium channels in rat through TrkB receptors is time and sensory experience dependent. *J Physiol* 2002; **542**: 413-429 [PMID: 12122142 DOI: 10.1113/jphysiol.2002.017376]

111 **Li HS**, Xu XZ, Montell C. Activation of a TRPC3-dependent cation current through the neurotrophin BDNF. *Neuron* 1999; **24**: 261-273 [PMID: 10677043 DOI: 10.1016/S0896-6273(00)80838-7]

112 **Ji Y**, Pang PT, Feng L, Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. *Nat Neurosci* 2005; **8**: 164-172 [PMID: 15665879 DOI: 10.1038/nn1381]

113 **Yoshii A**, Constantine-Paton M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. *Nat Neurosci* 2007; **10**: 702-711 [PMID: 17515902 DOI: 10.1038/nn1903]

114 **Caldeira MV**, Melo CV, Pereira DB, Carvalho RF, Carvalho AL, Duarte CB. BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. *Mol Cell Neurosci* 2007; **35**: 208-219 [PMID: 17428676 DOI: 10.1016/j.mcn.2007.02.019]

115 **Itami C**, Kimura F, Kohno T, Matsuoka M, Ichikawa M, Tsumoto T, Nakamura S. Brain-derived neurotrophic factor-dependent unmasking of "silent" synapses in the developing mouse barrel cortex. *Proc Natl Acad Sci U S A* 2003; **100**: 13069-13074 [PMID: 14557544 DOI: 10.1073/pnas.2131948100]

116 **Frerking M**, Malenka RC, Nicoll RA. Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus. *J Neurophysiol* 1998; **80**: 3383-3386 [PMID: 9862938]

117 **Bolton MM**, Pittman AJ, Lo DC. Brain-derived neurotrophic factor differentially regulates excitatory and inhibitory synaptic transmission in hippocampal cultures. *J Neurosci* 2000; **20**: 3221-3232 [PMID: 10777787]

118 **Baldelli P**, Novara M, Carabelli V, Hernández-Guijo JM, Carbone E. BDNF up-regulates evoked GABAergic transmission in developing hippocampus by potentiating presynaptic N- and P/Q-type Ca2+ channels signalling. *Eur J Neurosci* 2002; **16**: 2297-2310 [PMID: 12492424 DOI: 10.1046/j.1460-9568.2002.02313.x]

119 **Jovanovic JN**, Thomas P, Kittler JT, Smart TG, Moss SJ. Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability. *J Neurosci* 2004; **24**: 522-530 [PMID: 14724252 DOI: 10.1523/JNEUROSCI.3606-03.2004]

120 **Tanaka T**, Saito H, Matsuki N. Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. *J Neurosci* 1997; **17**: 2959-2966 [PMID: 9096132]

121 **Brünig I**, Penschuck S, Berninger B, Benson J, Fritschy JM. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABA(A) receptor surface expression. *Eur J Neurosci* 2001; **13**: 1320-1328 [PMID: 11298792 DOI: 10.1046/j.0953-816x.2001.01506.x]

122 **Wardle RA**, Poo MM. Brain-derived neurotrophic factor modulation of GABAergic synapses by postsynaptic regulation of chloride transport. *J Neurosci* 2003; **23**: 8722-8732 [PMID: 14507972]

123 **Mizoguchi Y**, Ishibashi H, Nabekura J. The action of BDNF on GABA(A) currents changes from potentiating to suppressing during maturation of rat hippocampal CA1 pyramidal neurons. *J Physiol* 2003; **548**: 703-709 [PMID: 12640007 DOI: 10.1113/jphysiol.2003.038935]

124 **Bliss TV**, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *J Physiol* 1973; **232**: 331-356 [PMID: 4727084]

125 **Malenka RC**, Bear MF. LTP and LTD: an embarrassment of riches. *Neuron* 2004; **44**: 5-21 [PMID: 15450156 DOI: 10.1016/j.neuron.2004.09.012]

126 **Panja D**, Bramham CR. BDNF mechanisms in late LTP formation: A synthesis and breakdown. *Neuropharmacology* 2014; **76 Pt C**: 664-676 [PMID: 23831365 DOI: 10.1016/j.neuropharm.2013.06.024]

127 **Patterson SL**, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. *Neuron* 1996; **16**: 1137-1145 [PMID: 8663990 DOI: 10.1016/S0896-6273(00)80140-3]

128 **Pozzo-Miller LD**, Gottschalk W, Zhang L, McDermott K, Du J, Gopalakrishnan R, Oho C, Sheng ZH, Lu B. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. *J Neurosci* 1999; **19**: 4972-4983 [PMID: 10366630]

129 **Heldt SA**, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. *Mol Psychiatry* 2007; **12**: 656-670 [PMID: 17264839 DOI: 10.1038/sj.mp.4001957]

130 **Minichiello L**, Korte M, Wolfer D, Kühn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R. Essential role for TrkB receptors in hippocampus-mediated learning. *Neuron* 1999; **24**: 401-414 [PMID: 10571233 DOI: 10.1016/S0896-6273(00)80853-3]

131 **Minichiello L**, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M. Mechanism of TrkB-mediated hippocampal long-term potentiation. *Neuron* 2002; **36**: 121-137 [PMID: 12367511 DOI: 10.1016/S0896-6273(02)00942-X]

132 **Tang SJ**, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. *Proc Natl Acad Sci U S A* 2002; **99**: 467-472 [PMID: 11756682 DOI: 10.1073/pnas.012605299]

133 **Zagrebelsky M**, Holz A, Dechant G, Barde YA, Bonhoeffer T, Korte M. The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. *J Neurosci* 2005; **25**: 9989-9999 [PMID: 16251447 DOI: 10.1523/JNEUROSCI.2492-05.2005]

134 **Dempster E**, Toulopoulou T, McDonald C, Bramon E, Walshe M, Filbey F, Wickham H, Sham PC, Murray RM, Collier DA. Association between BDNF val66 met genotype and episodic memory. *Am J Med Genet B Neuropsychiatr Genet* 2005; **134B**: 73-75 [PMID: 15719396 DOI: 10.1002/ajmg.b.30150]

135 **Ho BC**, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. *Arch Gen Psychiatry* 2006; **63**: 731-740 [PMID: 16818862 DOI: 10.1001/archpsyc.63.7.731]

136 **Miyajima F**, Ollier W, Mayes A, Jackson A, Thacker N, Rabbitt P, Pendleton N, Horan M, Payton A. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. *Genes Brain Behav* 2008; **7**: 411-417 [PMID: 17973920 DOI: 10.1111/j.1601-183X.2007.00363.x]

137 **Molendijk ML**, Bus BA, Spinhoven P, Kaimatzoglou A, Oude Voshaar RC, Penninx BW, van IJzendoorn MH, Elzinga BM. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume--a genuine effect or a winners curse? *Am J Med Genet B Neuropsychiatr Genet* 2012; **159B**: 731-740 [PMID: 22815222 DOI: 10.1002/ajmg.b.32078]

138 **Chen ZY**, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, Lee FS. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. *Science* 2006; **314**: 140-143 [PMID: 17023662 DOI: 10.1126/science.1129663]

139 **Ninan I**, Bath KG, Dagar K, Perez-Castro R, Plummer MR, Lee FS, Chao MV. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. *J Neurosci* 2010; **30**: 8866-8870 [PMID: 20592208 DOI: 10.1523/JNEUROSCI.1405-10.2010]

140 **Zuccato C**, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. *Nat Rev Neurol* 2009; **5**: 311-322 [PMID: 19498435 DOI: 10.1038/nrneurol.2009.54]

141 **Kim JM**, Stewart R, Kim SW, Yang SJ, Shin IS, Kim YH, Yoon JS. BDNF genotype potentially modifying the association between incident stroke and depression. *Neurobiol Aging* 2008; **29**: 789-792 [PMID: 17222482 DOI: 10.1016/j.neurobiolaging.2006.11.021]

142 **Gratacòs M**, González JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. *Biol Psychiatry* 2007; **61**: 911-922 [PMID: 17217930 DOI: 10.1016/j.biopsych.2006.08.025]

143 **Selkoe DJ**. Alzheimer's disease is a synaptic failure. *Science* 2002; **298**: 789-791 [PMID: 12399581 DOI: 10.1126/science.1074069]

144 **Braak H**, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol* 1991; **82**: 239-259 [PMID: 1759558]

145 **Masliah E**, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. *Neurosci Lett* 1994; **174**: 67-72 [PMID: 7970158]

146 **Tapia-Arancibia L**, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. *Brain Res Rev* 2008; **59**: 201-220 [PMID: 18708092 DOI: 10.1016/j.brainresrev.2008.07.007]

147 **Phillips HS**, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. *Neuron* 1991; **7**: 695-702 [PMID: 1742020]

148 **Connor B**, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. *Brain Res Mol Brain Res* 1997; **49**: 71-81 [PMID: 9387865]

149 **Holsinger RM**, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. *Brain Res Mol Brain Res* 2000; **76**: 347-354 [PMID: 10762711]

150 **Hock C**, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. *Arch Neurol* 2000; **57**: 846-851 [PMID: 10867782 DOI: 10.1001/archneur.57.6.846]

151 **Narisawa-Saito M**, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. *Neuroreport* 1996; **7**: 2925-2928 [PMID: 9116211]

152 **Laske C**, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. *J Psychiatr Res* 2007; **41**: 387-394 [PMID: 16554070 DOI: 10.1016/j.jpsychires.2006.01.014]

153 **Nagahara AH**, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nat Med* 2009; **15**: 331-337 [PMID: 19198615 DOI: 10.1038/nm.1912]

154 **Mucke L**, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci* 2000; **20**: 4050-4058 [PMID: 10818140]

155 **Peng S**, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, Mount HT, Mufson EJ, Salehi A, Fahnestock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. *J Neurosci* 2009; **29**: 9321-9329 [PMID: 19625522 DOI: 10.1523/JNEUROSCI.4736-08.2009]

156 **Devi L**, Ohno M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. *Neuropsychopharmacology* 2012; **37**: 434-444 [PMID: 21900882 DOI: 0.1038/npp.2011.191]

157 **Blurton-Jones M**, Kitazawa M, Martinez-Coria H, Castello NA, Müller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc Natl Acad Sci U S A* 2009; **106**: 13594-13599 [PMID: 19633196 DOI: 0.1073/pnas.0901402106]

158 **Reiner A**, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. *Proc Natl Acad Sci U S A* 1988; **85**: 5733-5737 [PMID: 2456581]

159 **Altar CA**, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. *Nature* 1997; **389**: 856-860 [PMID: 9349818 DOI: 10.1038/39885]

160 **Zuccato C**, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. *Nat Genet* 2003; **35**: 76-83 [PMID: 12881722 DOI: 10.1038/ng1219]

161 **Zuccato C**, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. *Prog Neurobiol* 2007; **81**: 294-330 [PMID: 17379385]

162 **Zuccato C**, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. *Brain Pathol* 2008; **18**: 225-238 [PMID: 18093249 DOI: 10.1111/j.1750-3639.2007.00111.x]

163 **Seo H**, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. *Ann Neurol* 2004; **56**: 319-328 [PMID: 15349858 DOI: 10.1002/ana.20207]

164 **Ferrer I**, Goutan E, Marín C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. *Brain Res* 2000; **866**: 257-261 [PMID: 10825501 DOI: 10.1016/S0006-8993(00)02237-X]

165 **Ciammola A**, Sassone J, Cannella M, Calza S, Poletti B, Frati L, Squitieri F, Silani V. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**: 574-577 [PMID: 17427191 DOI: 10.1002/ajmg.b.30501]

166 **Zuccato C**, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. *Pharmacol Res* 2005; **52**: 133-139 [PMID: 15967378 DOI: 10.1016/j.phrs.2005.01.001]

167 **Giralt A**, Carretón O, Lao-Peregrin C, Martín ED, Alberch J. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. *Mol Neurodegener* 2011; **6**: 71 [PMID: 21985529 DOI: 10.1186/1750-1326-6-71]

168 **Xie Y**, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. *J Neurosci* 2010; **30**: 14708-14718 [PMID: 21048129 DOI: 10.1523/JNEUROSCI.1637-10.2010]

169 **Spires TL**, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. *J Neurosci* 2004; **24**: 2270-2276 [PMID: 14999077 DOI: 10.1523/JNEUROSCI.1658-03.2004]

170 **Peng Q**, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. *Exp Neurol* 2008; **210**: 154-163 [PMID: 18096160 DOI: 10.1016/j.expneurol.2007.10.015]

171 **Jiang M**, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. *Hum Mol Genet* 2013; **22**: 2462-2470 [PMID: 23446639 DOI: 10.1093/hmg/ddt098]

172 **Baquet ZC**, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. *J Neurosci* 2004; **24**: 4250-4258 [PMID: 15115821 DOI: 10.1523/JNEUROSCI.3920-03.2004]

173 **Strand AD**, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. *J Neurosci* 2007; **27**: 11758-11768 [PMID: 17959817 DOI: 10.1523/JNEUROSCI.2461-07.2007]

174 **Schumacher J**, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmäl C, Höfels S, Zobel A, Illig T, Propping P, Holsboer F, Rietschel M, Nöthen MM, Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. *Biol Psychiatry* 2005; **58**: 307-314 [PMID: 16005437 DOI: 10.1016/j.biopsych.2005.04.006]

175 **Kishikawa S**, Li JL, Gillis T, Hakky MM, Warby S, Hayden M, MacDonald ME, Myers RH, Gusella JF. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. *Neurobiol Dis* 2006; **24**: 280-285 [PMID: 16962786 DOI: 10.1016/j.nbd.2006.07.008]

176 **Mai M**, Akkad AD, Wieczorek S, Saft C, Andrich J, Kraus PH, Epplen JT, Arning L. No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. *BMC Med Genet* 2006; **7**: 79 [PMID: 17096834 DOI: 10.1186/1471-2350-7-79]

177 **Metzger S**, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Mariotti C, Lange HW, Weirich-Schwaiger H, Wenning GK, Seppi K, Melegh B, Havasi V, Balikó L, Wieczorek S, Zaremba J, Hoffman-Zacharska D, Sulek A, Basak AN, Soydan E, Zidovska J, Kebrdlova V, Pandolfo M, Ribaï P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhrmann M, Riess O. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. *Hum Genet* 2006; **120**: 285-292 [PMID: 16847693 DOI: 10.1007/s00439-006-0221-2]

178 **Alberch J**, López M, Badenas C, Carrasco JL, Milà M, Muñoz E, Canals JM. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. *Neurology* 2005; **65**: 964-965 [PMID: 16186551]

179 **del Toro D**, Canals JM, Ginés S, Kojima M, Egea G, Alberch J. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. *J Neurosci* 2006; **26**: 12748-12757 [PMID: 17151278 DOI: 10.1523/JNEUROSCI.3873-06.2006]

180 **Numakawa T**, Yokomaku D, Richards M, Hori H, Adachi N, Kunugi H. Functional interactions between steroid hormones and neurotrophin BDNF. *World J Biol Chem* 2010; **1**: 133-143 [PMID: 21540998 DOI: 10.4331/wjbc.v1.i5.133]

181 **Duman RS**, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* 2006; **59**: 1116-1127 [PMID: 16631126 DOI: 10.1016/j.biopsych.2006.02.013]

182 **Lee BH**, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. *Psychiatry Investig* 2010; **7**: 231-235 [PMID: 21253405 DOI: 10.4306/pi.2010.7.4.231]

183 **Angelucci F**, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. *Mol Psychiatry* 2005; **10**: 345-352 [PMID: 15655562 DOI: 10.1038/sj.mp.4001637]

184 **Favalli G**, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. *J Psychiatr Res* 2012; **46**: 1-11 [PMID: 22030467 DOI: 10.1016/j.jpsychires.2011.09.022]

185 **Dwivedi Y**, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. *Arch Gen Psychiatry* 2003; **60**: 804-815 [PMID: 12912764 DOI: 10.1001/archpsyc.60.8.804]

186 **Karege F**, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. *Brain Res Mol Brain Res* 2005; **136**: 29-37 [PMID: 15893584]

187 **Guilloux JP**, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K, Tseng GC, Lewis DA, Sibille E. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. *Mol Psychiatry* 2012; **17**: 1130-1142 [PMID: 21912391 DOI: 10.1038/mp.2011.113]

188 **Tripp A**, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. *Am J Psychiatry* 2012; **169**: 1194-1202 [PMID: 23128924 DOI: 10.1176/appi.ajp.2012.12020248]

189 **Kim YK**, Lee HP, Won SD, Park EY, Lee HY, Lee BH, Lee SW, Yoon D, Han C, Kim DJ, Choi SH. Low plasma BDNF is associated with suicidal behavior in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; **31**: 78-85 [PMID: 16904252 DOI: 10.1016/j.pnpbp.2006.06.024]

190 **Karege F**, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. *Psychiatry Res* 2002; **109**: 143-148 [PMID: 11927139]

191 **Shimizu E**, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Biol Psychiatry* 2003; **54**: 70-75 [PMID: 12842310]

192 **Sen S**, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. *Biol Psychiatry* 2008; **64**: 527-532 [PMID: 18571629 DOI: 10.1016/j.biopsych.2008.05.005]

193 **Chen B**, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. *Biol Psychiatry* 2001; **50**: 260-265 [PMID: 11522260]

194 **Bayer TA**, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2000; **24**: 881-888 [PMID: 11041531 DOI: 10.1016/S0278-5846(00)00115-9]

195 **Pizarro JM**, Lumley LA, Medina W, Robison CL, Chang WE, Alagappan A, Bah MJ, Dawood MY, Shah JD, Mark B, Kendall N, Smith MA, Saviolakis GA, Meyerhoff JL. Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. *Brain Res* 2004; **1025**: 10-20 [PMID: 15464739 DOI: 10.1016/j.brainres.2004.06.085]

196 **Smith MA**, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. *J Neurosci* 1995; **15**: 1768-1777 [PMID: 7891134]

197 **Ueyama T**, Kawai Y, Nemoto K, Sekimoto M, Toné S, Senba E. Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. *Neurosci Res* 1997; **28**: 103-110 [PMID: 9220467 DOI: 10.1016/S0168-0102(97)00030-8]

198 **Roceri M**, Hendriks W, Racagni G, Ellenbroek BA, Riva MA. Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. *Mol Psychiatry* 2002; **7**: 609-616 [PMID: 12140784 DOI: 10.1038/sj.mp.4001036]

199 **Barbany G**, Persson H. Regulation of Neurotrophin mRNA Expression in the Rat Brain by Glucocorticoids. *Eur J Neurosci* 1992; **4**: 396-403 [PMID: 12106347 DOI: 10.1111/j.1460-9568.1992.tb00888.x]

200 **Schaaf MJ**, de Jong J, de Kloet ER, Vreugdenhil E. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. *Brain Res* 1998; **813**: 112-120 [PMID: 9824681 DOI: 10.1016/S0006-8993(98)01010-5]

201 **Jacobsen JP**, Mørk A. Chronic corticosterone decreases brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex, of the rat. *Brain Res* 2006; **1110**: 221-225 [PMID: 16876769 DOI: 10.1016/j.brainres.2006.06.077]

202 **Nibuya M**, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. *J Neurosci* 1995; **15**: 7539-7547 [PMID: 7472505]

203 **Russo-Neustadt A**, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. *Neuropsychopharmacology* 1999; **21**: 679-682 [PMID: 10516964 DOI: 10.1016/S0893-133X(99)00059-7]

204 **Balu DT**, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. *Brain Res* 2008; **1211**: 37-43 [PMID: 18433734 DOI: 10.1016/j.brainres.2008.03.023]

205 **Coppell AL**, Pei Q, Zetterström TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. *Neuropharmacology* 2003; **44**: 903-910 [PMID: 12726822 DOI: 10.1016/S0028-3908(03)00077-7]

206 **De Foubert G**, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O'Neill MJ, Zetterström TS. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. *Neuroscience* 2004; **128**: 597-604 [PMID: 15381288 DOI: 10.1016/j.neuroscience.2004.06.054]

207 **Rogóz Z**, Skuza G, Legutko B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. *J Physiol Pharmacol* 2005; **56**: 661-671 [PMID: 16391422]

208 **Angelucci F,** Aloe L, Jiménez-Vasquez P, Mathé AA. J ECT. Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. [*J ECT*](http://www.ncbi.nlm.nih.gov/pubmed/?term=Angelucci+F%2C+Aloe+L%2C+Jim%C3%A9nez-Vasquez+P%2C+Math%C3%A9+AA.+J+ECT.+Electroconvulsive+stimuli+alter+the+regional+concentrations+of+nerve+growth+factor%2C+brain-derived+neurotrophic+factor%2C+and+glial+cell+line-derived+neurotrophic+factor+in+adult+rat+brain) 2002; **18:** 138-143 [PMID: 12394532]

209 **Smith MA**, Zhang LX, Lyons WE, Mamounas LA. Anterograde transport of endogenous brain-derived neurotrophic factor in hippocampal mossy fibers. *Neuroreport* 1997; **8**: 1829-1834 [PMID: 9223060]

210 **Altar CA**, Whitehead RE, Chen R, Wörtwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. *Biol Psychiatry* 2003; **54**: 703-709 [PMID: 14512210]

211 **Altar CA**, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman YV, Young TA, Charles V, Palfreyman MG. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. *J Neurosci* 2004; **24**: 2667-2677 [PMID: 15028759 DOI: 10.1523/JNEUROSCI.5377-03.2004]

212 **Liu X**, Qi Q, Xiao G, Li J, Luo HR, Ye K. O-methylated metabolite of 7,8-dihydroxyflavone activates TrkB receptor and displays antidepressant activity. *Pharmacology* 2013; **91**: 185-200 [PMID: 23445871 DOI: 10.1159/000346920]

213 **Siuciak JA**, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). *Pharmacol Biochem Behav* 1997; **56**: 131-137 [PMID: 8981620 DOI: 10.1016/S0091-3057(96)00169-4]

214 **Saarelainen T**, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castrén E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. *J Neurosci* 2003; **23**: 349-357 [PMID: 12514234]

215 **Rantamäki T**, Vesa L, Antila H, Di Lieto A, Tammela P, Schmitt A, Lesch KP, Rios M, Castrén E. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. *PLoS One* 2011; **6**: e20567 [PMID: 21666748 DOI: 10.1371/journal.pone.0020567]

216 **Verhagen M**, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vásquez A, Buitelaar JK, Franke B. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. *Mol Psychiatry* 2010; **15**: 260-271 [PMID: 18852698 DOI: 10.1038/mp.2008.109]

217 **de Kloet ER**, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci* 2005; **6**: 463-475 [PMID: 15891777 DOI: 10.1038/nrn1683]

218 **Pariante CM**, Lightman SL. The HPA axis in major depression: classical theories and new developments. *Trends Neurosci* 2008; **31**: 464-468 [PMID: 18675469 DOI: 10.1016/j.tins.2008.06.006]

219 **Numakawa T**, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H. Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. *Proc Natl Acad Sci U S A* 2009; **106**: 647-652 [PMID: 19126684 DOI: 10.1073/pnas.0800888106]

220 **Jeanneteau F**, Garabedian MJ, Chao MV. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. *Proc Natl Acad Sci U S A* 2008; **105**: 4862-4867 [PMID: 18347336 DOI: 10.1073/pnas.0709102105]

221 **Lambert WM**, Xu CF, Neubert TA, Chao MV, Garabedian MJ, Jeanneteau FD. Brain-derived neurotrophic factor signaling rewrites the glucocorticoid transcriptome via glucocorticoid receptor phosphorylation. *Mol Cell Biol* 2013; **33**: 3700-3714 [PMID: 23878391 DOI: 10.1128/MCB.00150-13]

222 **Jeanneteau F**, Chao MV. Are BDNF and glucocorticoid activities calibrated? *Neuroscience* 2013; **239**: 173-195 [PMID: 23022538 DOI: 10.1016/j.neuroscience.2012.09.017]

223 The National Institute of Mental Health (NIMH) website; http: //www.nimh.nih.gov/health/topics/schizophrenia/index.shtml

224 **Akbarian S**, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. *Arch Gen Psychiatry* 1995; **52**: 258-266 [PMID: 7702443 DOI: 10.1001/archpsyc.1995.03950160008002]

225 **Glantz LA**, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. *Arch Gen Psychiatry* 1997; **54**: 660-669 [PMID: 9236550 DOI: 10.1001/archpsyc.1997.01830190088009]

226 **Glantz LA**, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry* 2000; **57**: 65-73 [PMID: 10632234 DOI: 10.1001/archpsyc.57.1.65]

227 **Knable MB**, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF; Stanley Neuropathology Consortium. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. *Mol Psychiatry* 2004; **9**: 609-20, 544 [PMID: 14708030 DOI: 10.1038/sj.mp.4001471]

228 **Vasic N**, Connemann BJ, Wolf RC, Tumani H, Brettschneider J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? *Eur Arch Psychiatry Clin Neurosci* 2012; **262**: 375-391 [PMID: 22173848 DOI: 10.1007/s00406-011-0280-9]

229 **Vinogradov S**, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? *Biol Psychiatry* 2009; **66**: 549-553 [PMID: 19368899 DOI: 10.1016/j.biopsych.2009.02.017]

230 **Takahashi M**, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, Koizumi S, Wakabayashi K, Takahashi H, Someya T, Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. *Mol Psychiatry* 2000; **5**: 293-300 [PMID: 10889532 DOI: 10.1038/sj.mp.4000718]

231 **Durany N**, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. *Schizophr Res* 2001; **52**: 79-86 [PMID: 11595394]

232 **Weickert CS**, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. *Mol Psychiatry* 2003; **8**: 592-610 [PMID: 12851636 DOI: 10.1038/sj.mp.4001308]

233 **Hashimoto T**, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. *J Neurosci* 2005; **25**: 372-383 [PMID: 15647480 DOI: 10.1523/JNEUROSCI.4035-04.2005]

234 **Issa G**, Wilson C, Terry AV, Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. *Neurobiol Dis* 2010; **39**: 327-333 [PMID: 20451611 DOI: 10.1016/j.nbd.2010.04.017]

235 **Grillo RW**, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. *J Psychiatr Res* ; **41**: 31-35 [PMID: 16546213 DOI: 10.1016/j.jpsychires.2006.01.005]

236 **Lee AH**, Lange C, Ricken R, Hellweg R, Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. *J Clin Psychopharmacol* 2011; **31**: 334-336 [PMID: 21508862 DOI: 10.1097/JCP.0b013e31821895c1]

237 **Green MJ**, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. *Mol Psychiatry* 2011; **16**: 960-972 [PMID: 20733577 DOI: 10.1038/mp.2010.88]

238 **Snigdha S**, Neill JC, McLean SL, Shemar GK, Cruise L, Shahid M, Henry B. Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. *J Mol Neurosci* 2011; **43**: 337-345 [PMID: 20852970 DOI: 10.1007/s12031-010-9447-5]

239 **Fumagalli F**, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, Gennarelli M, Racagni G, Riva MA. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. *J Neurosci Res* 2003; **72**: 622-628 [PMID: 12749027 DOI: 10.1002/jnr.10609]

240 **Ashe PC**, Chlan-Fourney J, Juorio AV, Li XM. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. *Brain Res* 2002; **956**: 126-135 [PMID: 12426055 DOI: 10.1016/S0006-8993(02)03176-1]

241 **Angelucci F**, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. *J Neurosci Res* 2000; **60**: 783-794 [PMID: 10861791 DOI: 10.1002/1097-4547(20000615)60: 6<783: : AID-JNR11>3.0.CO; 2-M]

242 **Parikh V**, Khan MM, Mahadik SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. *Neurosci Lett* 2004; **356**: 135-139 [PMID: 14746882 DOI: 10.1016/j.neulet.2003.10.079]

243 **Pillai A**, Terry AV, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. *Schizophr Res* 2006; **82**: 95-106 [PMID: 16442781 DOI: 10.1016/j.schres.2005.11.021]

244 **Morris BJ**, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. *Curr Opin Pharmacol* 2005; **5**: 101-106 [PMID: 15661633]

245 **Javitt DC**, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. *Am J Psychiatry* 1991; **148**: 1301-1308 [PMID: 1654746]

246 **Takahashi M**, Kakita A, Futamura T, Watanabe Y, Mizuno M, Sakimura K, Castren E, Nabeshima T, Someya T, Nawa H. Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. *J Neurochem* 2006; **99**: 770-780 [PMID: 16903871 DOI: 10.1111/j.1471-4159.2006.04106.x]

247 **Hock C**, Heese K, Müller-Spahn F, Hulette C, Rosenberg C, Otten U. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. *Neurosci Lett* 1998; **241**: 151-154 [PMID: 9507943 DOI: 10.1016/S0304-3940(98)00019-6]

248 **Gervasoni N**, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. *Neuropsychobiology* 2005; **51**: 234-238 [PMID: 15897674 DOI: 10.1159/000085725]

249 **Rasmusson AM**, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. *Neuropsychopharmacology* 2002; **27**: 133-142 [PMID: 12093587 DOI: 10.1016/S0893-133X(02)00286-5]

250 **Roceri M**, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. *Biol Psychiatry* 2004; **55**: 708-714 [PMID: 15038999 DOI: 10.1016/j.biopsych.2003.12.011]

251 **Russo-Neustadt AA**, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. *Neuropsychopharmacology* 2004; **29**: 2189-2199 [PMID: 15199375 DOI: 10.1038/sj.npp.1300514]

252 **Xiu MH**, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry* 2009; **33**: 1508-1512 [PMID: 19720106 DOI: 10.1016/j.pnpbp.2009.08.011]

253 **Hung YY**, Huang TL. Lower serum tropomyosin receptor kinase B levels in patients with schizophrenia. *Biomed J* 2013; **36**: 132-136 [PMID: 23806883 DOI: 10.4103/2319-4170.113229]

254 **Pillai A**. Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. *PLoS One* 2008; **3**: e1784 [PMID: 18335055 DOI: 10.1371/journal.pone.0001784]

255 **Weickert CS**, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, Weinberger DR, Kleinman JE. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. *Mol Psychiatry* 2005; **10**: 637-650 [PMID: 15940304 DOI: 10.1038/sj.mp.4001678]

256 **Wong J**, Rothmond DA, Webster MJ, Weickert CS. Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia. *Schizophr Bull* 2013; **39**: 130-140 [PMID: 21795612 DOI: 10.1093/schbul/sbr070]

257 **Toyooka K**, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. *Psychiatry Res* 2002; **110**: 249-257 [PMID: 12127475 DOI: 10.1016/S0165-1781(02)00127-0]

258 **Tan YL**, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. *Neurosci Lett* 2005; **382**: 27-32 [PMID: 15911116 DOI: 10.1016/j.neulet.2005.02.054]

259 **Palomino A**, Vallejo-Illarramendi A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F, González-García G, Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. *Schizophr Res* 2006; **86**: 321-322 [PMID: 16829047 DOI: 10.1016/j.schres.2006.05.028]

260 **Jindal RD**, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS. Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. *Schizophr Res* 2010; **119**: 47-51 [PMID: 20096541 DOI: 10.1016/j.schres.2009.12.035]

261 **Iritani S**, Niizato K, Nawa H, Ikeda K, Emson PC. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; **27**: 801-807 [PMID: 12921913 DOI: 10.1016/S0278-5846(03)00112-X]

262 **Bai O**, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. *J Neurosci Res* 2003; **71**: 127-131 [PMID: 12478621 DOI: 10.1002/jnr.10440]

**P-Reviewer:** Chakrabarti, S, Forero DA

**S-Editor:** Song XX **L-Editor:** **E-Editor:**



**Figure 1 Schematic illustration of the activity-dependent regulators for BDNF gene transcription.** A variety of transcriptional factors and regulators participate in the activity-induced transcription of BDNF. *BDNF* gene structure and Ca2+-dependent regulation in BDNF exon IV and epigenetic regulation at the exon IX promoter region are presented. We referred to the description by Zheng *et al*[38], also see [180]. BDNF: Brain-derived neurotrophic factor.



**Figure 2 Schematic illustration of activity-dependent brain-derived neurotrophic factor secretion.** A possible mechanism of intracellular Ca2+-dependent secretion of BDNF suggested in literature. Ca2+ influx through NMDA receptor/L-type VGCC and subsequent Ca2+ release of internal stores *via* ryanodine receptors are required for secretion. CaMKII, PKA, synaptotagmin IV, and CAPS2 also critically contribute to the membrane fusion process of BDNF-containing vesicles. VGCC: L-type voltage-gated calcium channels, CaMKII: calcium/calmodulin-dependent protein kinase II, PKA: protein kinase A, CAPS2: Ca2+-dependent activator protein for secretion 2; BDNF: Brain-derived neurotrophic factor.



**Figure 3 Molecular mechanisms of phencyclidine-induced synaptic loss as a cellular model of schizophrenia.** Phencyclidine decreased the number of synaptic sites in cultured cortical neurons through blockade of Ca2+ influx *via* NMDARs and resultant suppression of BDNF secretion. The impairment in BDNF secretion reduced TrkB activation and resulted in decreased synaptic connectivity[15].